Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2022-06-27,13.949999809265137,13.949999809265137,11.050000190734863,13.0,9963,0.0,0.0,,,,,,,,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-06-28,10.399999618530273,13.350000381469727,10.399999618530273,12.949999809265137,1964,0.0,0.0,,,,,,,0.0,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-06-29,13.100000381469727,13.300000190734863,12.899999618530273,12.899999618530273,418,0.0,0.0,,,,,,,0.0,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-06-30,13.0,13.0,12.899999618530273,13.0,1200,0.0,0.0,,,,,,,52.75908479138628,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-01,12.899999618530273,12.899999618530273,12.899999618530273,12.899999618530273,70,0.0,0.0,,,,,,,33.64362580048855,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-04,12.949999809265137,12.949999809265137,12.0,12.649999618530273,567,0.0,0.0,,,,,,,17.030760297413465,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-05,12.649999618530273,12.649999618530273,11.100000381469727,12.600000381469727,76,0.0,0.0,,,,,,,15.393604086900638,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-06,11.949999809265137,13.0,11.25,12.899999618530273,5737,0.0,0.0,,,,,,,47.81092586682478,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-07,12.0,12.899999618530273,12.0,12.449999809265137,10243,0.0,0.0,,,,,,,29.53218230113039,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-08,13.0,13.0,12.550000190734863,12.550000190734863,58,0.0,0.0,12.789999866485596,,,-1.876463473464283,,,35.43912308574542,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-11,11.949999809265137,12.100000381469727,11.800000190734863,12.0,1922,0.0,0.0,12.689999866485596,,,-5.437351250947545,,,23.681367296510274,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-12,12.0,12.149999618530273,12.0,12.149999618530273,2622,0.0,0.0,12.609999847412109,,,-3.6479003524828664,,,30.45781083851537,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-13,12.100000381469727,12.149999618530273,12.0,12.149999618530273,9949,0.0,0.0,12.53499984741211,,,-3.071401943106688,,,30.45781083851537,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-14,11.199999809265137,11.199999809265137,11.199999809265137,11.199999809265137,170,0.0,0.0,12.354999828338624,,,-9.348442210612316,,,18.434813988426725,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-15,11.199999809265137,12.100000381469727,11.199999809265137,11.649999618530273,5257,0.0,0.0,12.229999828338624,,,-4.74243841332204,,,32.10633400660873,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-18,11.399999618530273,12.899999618530273,11.300000190734863,12.899999618530273,599,0.0,0.0,12.254999828338622,,,5.263156256437843,,,54.78010959371425,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-19,12.75,12.75,12.75,12.75,200,0.0,0.0,12.269999790191651,,,3.911982216919431,,,52.51373187566391,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-20,11.199999809265137,12.75,11.199999809265137,12.550000190734863,473,0.0,0.0,12.234999847412109,,,2.5745839579179237,,,49.569013406088736,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-21,12.25,12.25,12.25,12.25,1200,0.0,0.0,12.214999866485595,,,0.28653404745779154,,,45.45184138294719,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-22,11.199999809265137,12.25,11.199999809265137,12.050000190734863,1638,0.0,0.0,12.164999866485596,,,-0.9453323223418627,,,42.893975488370515,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-25,12.050000190734863,12.850000381469727,12.050000190734863,12.75,929,0.0,0.0,12.239999866485595,,,4.166667802920804,,,52.88743888779169,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-26,12.449999809265137,13.850000381469727,12.449999809265137,13.75,3221,0.0,0.0,12.399999904632569,,,10.88709762701755,,,62.88094299178779,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-27,13.899999618530273,13.949999809265137,12.050000190734863,13.949999809265137,9474,0.0,0.0,12.579999923706055,,,10.890301223113852,,,64.50271744055962,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-28,13.600000381469727,15.0,13.600000381469727,14.850000381469727,21553,0.0,0.0,12.944999980926514,,,14.716109720742274,,,70.70539320501774,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-07-29,14.699999809265137,14.699999809265137,14.0,14.699999809265137,2226,0.0,0.0,13.25,,,10.943394786906692,,,68.5552878330922,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-01,14.75,14.75,14.699999809265137,14.699999809265137,72,0.0,0.0,13.430000019073486,,,9.456439228503191,,,68.5552878330922,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-02,13.800000190734863,16.850000381469727,13.800000190734863,16.399999618530273,7400,0.0,0.0,13.794999980926514,,,18.88365089674179,,,77.53465334963676,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-03,15.899999618530273,24.399999618530273,15.899999618530273,16.399999618530273,12340,0.0,0.0,14.179999923706054,,,15.655851246605682,,,77.53465334963676,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-04,16.399999618530273,18.149999618530273,15.550000190734863,17.850000381469727,1892,0.0,0.0,14.739999961853027,,,21.099053104920966,,,82.48287886860278,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-05,16.799999237060547,17.850000381469727,15.800000190734863,17.850000381469727,3731,0.0,0.0,15.319999980926514,,,16.514362948388232,,,82.48287886860278,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-08,18.200000762939453,20.600000381469727,18.0,18.0,2333,0.0,0.0,15.844999980926513,,,13.600505027879947,,,82.93386463671453,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-09,19.0,19.0,18.649999618530273,18.649999618530273,1428,0.0,0.0,16.33499994277954,,,14.172021327579001,,,84.76435926047395,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-10,17.5,18.5,17.5,18.5,1700,0.0,0.0,16.789999961853027,,,10.184633960882087,,,82.56354525552,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-11,18.950000762939453,18.950000762939453,17.450000762939453,17.5,557,0.0,0.0,17.054999923706056,,,2.6092059705928468,,,69.59118960516221,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-12,17.5,19.149999618530273,17.0,18.200000762939453,7066,0.0,0.0,17.405000019073487,,,4.567657242141652,,,72.81150811828222,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-15,18.100000381469727,18.100000381469727,17.0,17.25,543,0.0,0.0,17.660000038146972,,,-2.3216310150698756,,,63.05238025479142,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-16,17.0,17.0,16.100000381469727,16.950000762939453,1566,0.0,0.0,17.71500015258789,,,-4.318370776512146,,,60.30362979426435,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-17,17.0,17.0,16.5,16.5,971,0.0,0.0,17.725000190734864,,,-6.911143455869698,,,56.33628609840289,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-18,16.549999237060547,17.299999237060547,16.549999237060547,17.299999237060547,1474,0.0,0.0,17.670000076293945,,,-2.093949279206802,,,61.22074878985207,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-19,17.399999618530273,17.75,16.049999237060547,16.75,865,0.0,0.0,17.560000038146974,14.45874993801117,,-4.61275647145414,21.4489503825141,,56.538070670869295,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-22,17.0,17.0,16.75,16.75,7,0.0,0.0,17.435000038146974,14.55249993801117,,-3.9288789024848043,19.807593969519324,,56.538070670869295,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-23,16.600000381469727,16.600000381469727,16.600000381469727,16.600000381469727,7,0.0,0.0,17.23000011444092,14.643749952316284,,-3.656411658657932,17.661119389132654,,55.20254511014732,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-24,16.0,17.0,16.0,16.5,146,0.0,0.0,17.030000114440917,14.733749961853027,,-3.1121556716343926,15.584967564490254,,54.281962125978254,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-25,16.25,17.0,16.0,17.0,525,0.0,0.0,16.98000011444092,14.833749961853027,,0.11778495538449013,14.468695765448805,,58.04899366445141,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-26,16.0,16.450000762939453,13.050000190734863,16.450000762939453,4423,0.0,0.0,16.80500011444092,14.922499990463256,,-2.1124626544715497,12.615179260718643,,52.88678444999843,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-29,16.450000762939453,16.450000762939453,16.450000762939453,16.450000762939453,185,0.0,0.0,16.725000190734864,15.017500019073486,,-1.644241701998617,11.370069382338668,,52.88678444999843,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-30,16.25,16.25,14.800000190734863,15.949999809265137,137,0.0,0.0,16.625000095367433,15.10125000476837,,-4.060152073565314,10.090224915936911,,48.353175856606576,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-08-31,14.199999809265137,15.0,14.199999809265137,15.0,559,0.0,0.0,16.47500009536743,15.153750014305114,,-8.952959555867821,8.718964479518661,,41.13756913661685,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-01,13.100000381469727,14.350000381469727,12.5,14.350000381469727,873,0.0,0.0,16.180000209808348,15.201250028610229,,-11.31025837211839,6.438616425333551,,37.062315309674744,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-02,12.550000190734863,13.850000381469727,12.0,13.699999809265137,5703,0.0,0.0,15.875000190734863,15.230000019073486,,-13.700789639921535,4.235063498710453,,33.48950404280764,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-05,13.699999809265137,15.399999618530273,13.699999809265137,15.199999809265137,1141,0.0,0.0,15.720000171661377,15.310000014305114,,-3.307890309910118,2.6779892682767725,,46.3440710025029,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-06,12.0,15.199999809265137,12.0,15.149999618530273,847,0.0,0.0,15.575000095367432,15.385000014305115,,-2.728734987061537,1.2349696515154593,,46.02475269879926,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-07,15.149999618530273,15.149999618530273,15.149999618530273,15.149999618530273,0,0.0,0.0,15.440000057220459,15.460000014305114,,-1.8782411762658504,-0.12936582837095392,,46.02475269879926,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-08,14.949999809265137,14.949999809265137,13.800000190734863,14.850000381469727,3179,0.0,0.0,15.225000095367431,15.55125002861023,,-2.463052292602658,-2.097901664770258,,43.919034397127646,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-09,13.75,14.850000381469727,13.75,14.850000381469727,975,0.0,0.0,15.065000057220459,15.631250047683716,,-1.42714686315375,-3.6225509075466795,,43.91903439712764,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-12,14.949999809265137,15.0,14.949999809265137,15.0,98,0.0,0.0,14.919999980926514,15.68375005722046,,0.5361931580144551,-4.869690434414512,,45.36844599953147,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-13,15.0,15.199999809265137,14.550000190734863,15.199999809265137,7413,0.0,0.0,14.844999980926513,15.745000052452088,,2.391376414919115,-5.716100784549768,,47.32331993818393,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-14,15.199999809265137,15.199999809265137,15.199999809265137,15.199999809265137,0,0.0,0.0,14.864999961853027,15.811250042915344,,2.2536148555115774,-5.984663315639042,,47.32331993818392,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-15,15.199999809265137,15.199999809265137,13.100000381469727,15.149999618530273,280,0.0,0.0,14.944999885559081,15.8837500333786,,1.3716944432316616,-5.910129193967424,,46.83738371183742,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-16,15.149999618530273,15.149999618530273,15.149999618530273,15.149999618530273,0,0.0,0.0,15.089999866485595,15.961250019073486,,0.39761267445691617,-5.458533332582085,,46.83738371183742,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-19,15.149999618530273,15.149999618530273,15.149999618530273,15.149999618530273,0,0.0,0.0,15.08499984741211,16.021250009536743,,0.43089010126383476,-5.843802209985642,,46.83738371183742,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-20,15.149999618530273,15.149999618530273,15.149999618530273,15.149999618530273,0,0.0,0.0,15.08499984741211,16.05625,,0.43089010126383476,-6.049047271859174,,46.83738371183742,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-21,15.149999618530273,15.149999618530273,15.149999618530273,15.149999618530273,0,0.0,0.0,15.08499984741211,16.08624999523163,,0.43089010126383476,-6.224260770013614,,46.83738371183742,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-22,12.949999809265137,14.149999618530273,11.0,14.100000381469727,437,0.0,0.0,15.009999847412109,16.06749999523163,,-6.062621420341163,-6.581609759659904,,35.68963994150714,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-23,14.25,15.0,13.149999618530273,14.75,13962,0.0,0.0,14.999999809265137,16.06875,,-1.666665416293663,-6.651109705078888,,44.496542467667275,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-26,12.850000381469727,18.0,12.850000381469727,14.850000381469727,3213,0.0,0.0,14.984999847412109,16.072500014305113,,-0.9008973461264088,-6.7662166179815815,,45.727922018499314,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-27,12.899999618530273,14.75,12.899999618530273,14.449999809265137,6848,0.0,0.0,14.90999984741211,16.023750019073486,,-3.0851780204867922,-6.950621236200331,,41.73898296298899,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-28,13.300000190734863,14.649999618530273,12.850000381469727,14.649999618530273,405,0.0,0.0,14.854999828338624,15.980000019073486,,-1.380008160062547,-7.0400512477601955,,44.35278688913381,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-29,13.600000381469727,18.450000762939453,13.600000381469727,17.149999618530273,5775,0.0,0.0,15.054999828338623,15.9625,,13.915641408697654,-5.685200762169944,,65.30581347146881,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-09-30,15.0,16.450000762939453,13.949999809265137,15.350000381469727,605,0.0,0.0,15.074999904632568,15.9,,1.8242154466127096,-5.188679845078191,,50.54793949212406,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-03,15.350000381469727,15.350000381469727,15.350000381469727,15.350000381469727,2000,0.0,0.0,15.094999980926513,15.833750009536743,,1.6893037486944202,-4.6656668708630455,,50.54793949212406,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-04,14.050000190734863,15.300000190734863,14.050000190734863,15.300000190734863,3553,0.0,0.0,15.110000038146973,15.750000023841858,,1.2574464070695732,-4.063491966514751,,50.182602339489875,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-05,15.300000190734863,15.300000190734863,15.300000190734863,15.300000190734863,0,0.0,0.0,15.125000095367431,15.670000028610229,,1.157025416621531,-3.477982975416328,,50.182602339489875,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-06,15.300000190734863,15.300000190734863,15.300000190734863,15.300000190734863,0,0.0,0.0,15.245000076293945,15.615000033378601,,0.3607747731431248,-2.36951621065479,,50.182602339489875,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-07,15.300000190734863,15.300000190734863,15.300000190734863,15.300000190734863,45,0.0,0.0,15.300000095367432,15.542500019073486,,6.233165404634814e-07,-1.560237564152888,,50.182602339489875,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-10,13.600000381469727,15.350000381469727,13.600000381469727,15.350000381469727,191,0.0,0.0,15.350000095367431,15.49500002861023,,1.8638585918886232e-06,-0.9357853047761768,,50.662234824558915,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-11,15.050000190734863,15.050000190734863,14.050000190734863,14.399999618530273,4445,0.0,0.0,15.345000076293946,15.43125,,-6.158360723787658,-0.5589302467788049,,42.32436709271997,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-12,15.300000190734863,15.300000190734863,15.300000190734863,15.300000190734863,377,0.0,0.0,15.410000133514405,15.401250004768372,,-0.7138218158759687,0.05681440625484492,,50.61633300549058,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-13,15.300000190734863,15.5,13.850000381469727,15.25,4615,0.0,0.0,15.220000171661377,15.350000023841858,,0.19710793692683634,-0.8469045731502465,,50.18466513133671,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-14,15.5,19.200000762939453,14.949999809265137,16.5,17371,0.0,0.0,15.335000133514404,15.343750023841858,,7.596999389256652,-0.057025761719646906,,59.486730344694465,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-17,18.450000762939453,18.5,17.0,18.450000762939453,4811,0.0,0.0,15.645000171661376,15.386250042915345,,17.929054397576323,1.6816971518357333,,69.16113354838612,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-18,17.75,18.5,15.350000381469727,18.5,25226,0.0,0.0,15.96500015258789,15.433750033378601,,15.87848307662679,3.4421324568582095,,69.36314886334023,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-19,18.450000762939453,18.5,15.949999809265137,16.049999237060547,5445,0.0,0.0,16.04000005722046,15.422500014305115,,0.06233902621206852,4.00389069439186,,51.54508002691594,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-20,18.0,18.0,16.0,17.950000762939453,5783,0.0,0.0,16.30500011444092,15.4462500333786,,10.088933682629046,5.5596023578965825,,60.10423747716837,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-21,18.200000762939453,18.200000762939453,17.649999618530273,17.799999237060547,1450,0.0,0.0,16.555000019073486,15.479999995231628,,7.5203818577629855,6.94444460060074,,59.214932376824045,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-24,18.200000762939453,18.200000762939453,18.200000762939453,18.200000762939453,25,0.0,0.0,16.840000057220458,15.52374999523163,,8.076013664476624,8.478943956151934,,60.87729299940037,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-25,18.100000381469727,18.100000381469727,15.350000381469727,16.600000381469727,6227,0.0,0.0,17.060000133514404,15.540000009536744,,-2.696364293344914,9.781210573004188,,51.78504032123011,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-26,15.0,15.149999618530273,14.800000190734863,14.800000190734863,6818,0.0,0.0,17.010000133514403,15.535000014305115,,-12.99235699842958,9.494690169623823,,43.85040577716558,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-27,17.049999237060547,17.950000762939453,15.25,16.25,6806,0.0,0.0,17.110000133514404,15.582500004768372,,-5.026301150225414,9.802664067245981,,50.43833031985566,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-28,16.25,16.25,14.050000190734863,15.5,2559,0.0,0.0,17.010000133514403,15.627500009536742,,-8.877131814592317,8.846585334403995,,47.34414531868516,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-10-31,14.5,15.0,14.5,15.0,325,0.0,0.0,16.66500005722046,15.622500014305114,,-9.990999408962283,6.673067959422349,,45.34692118397237,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-01,15.399999618530273,15.399999618530273,14.25,14.800000190734863,586,0.0,0.0,16.295000076293945,15.61375002861023,,-9.174592688305758,4.3631417592532875,,44.537580438836095,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-02,15.0,15.0,14.649999618530273,14.699999809265137,196,0.0,0.0,16.160000133514405,15.6025000333786,,-9.034655397194937,3.5731459634234164,,44.11363187142406,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-03,14.699999809265137,15.399999618530273,14.649999618530273,15.350000381469727,518,0.0,0.0,15.900000095367432,15.615000033378601,,-3.4591176767222223,1.8251685006699616,,47.60483057006177,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-04,15.350000381469727,15.399999618530273,14.300000190734863,14.949999809265137,2127,0.0,0.0,15.615000152587891,15.617500019073486,,-4.258727741431005,-0.01600682876607381,,45.71234014247209,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-07,14.350000381469727,15.199999809265137,14.350000381469727,15.199999809265137,818,0.0,0.0,15.315000057220459,15.622500014305114,,-0.7508994288322178,-1.968314653884368,,47.12709095769311,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-08,15.0,15.199999809265137,14.300000190734863,15.199999809265137,266,0.0,0.0,15.175,15.622500014305114,,0.16474338889710713,-2.8644584022745994,,47.12709095769311,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-09,15.149999618530273,15.149999618530273,15.149999618530273,15.149999618530273,25,0.0,0.0,15.209999942779541,15.621250009536743,,-0.394479450854641,-2.6326322573810295,,46.84393012859708,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-10,13.949999809265137,14.850000381469727,13.949999809265137,14.850000381469727,2050,0.0,0.0,15.069999980926514,15.61375002861023,,-1.459851358561595,-3.4825077043462485,,45.093248252717856,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-11,12.25,14.850000381469727,12.25,14.800000190734863,511,0.0,0.0,15.0,15.605000042915345,,-1.3333320617675781,-3.8769627763635546,,44.79278032232772,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-14,14.800000190734863,14.800000190734863,14.0,14.649999618530273,758,0.0,0.0,14.964999961853028,15.592500042915344,,-2.104913759610528,-4.024371199841224,,43.848826991631505,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-15,14.550000190734863,14.550000190734863,13.5,14.449999809265137,2378,0.0,0.0,14.929999923706054,15.575000047683716,,-3.215004131907375,-4.141252789746121,,42.56094775249588,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-16,14.449999809265137,14.449999809265137,14.449999809265137,14.449999809265137,0,0.0,0.0,14.904999923706054,15.557500052452088,,-3.0526676737330956,-4.1941194057279825,,42.56094775249588,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-17,14.899999618530273,15.199999809265137,14.100000381469727,15.199999809265137,1353,0.0,0.0,14.889999866485596,15.585000038146973,,2.0819338183963905,-4.459417195766726,,49.066998959760134,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-18,15.199999809265137,15.199999809265137,15.199999809265137,15.199999809265137,8,0.0,0.0,14.914999866485596,15.5962500333786,,1.9108276589391273,-4.368038249162553,,49.066998959760134,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-21,15.199999809265137,15.199999809265137,15.199999809265137,15.199999809265137,0,0.0,0.0,14.914999866485596,15.605000019073486,,1.9108276589391273,-4.421660696856939,,49.066998959760134,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-22,14.300000190734863,14.300000190734863,14.100000381469727,14.149999618530273,2424,0.0,0.0,14.80999984741211,15.597500014305115,,-4.456449937081967,-5.048887104797285,,40.955445560686144,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-23,14.0,14.0,14.0,14.0,621,0.0,0.0,14.694999885559081,15.581250023841857,,-4.729499087931702,-5.687927072132649,,39.93965470029245,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-24,13.949999809265137,14.350000381469727,13.5,13.949999809265137,545,0.0,0.0,14.604999828338624,15.50125002861023,,-4.484765674577868,-5.781793072283987,,39.587191703145486,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-25,13.899999618530273,14.949999809265137,13.699999809265137,14.800000190734863,434,0.0,0.0,14.604999828338624,15.487500023841857,,1.3351616890667337,-5.698144917802678,,47.990062717353666,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-28,14.449999809265137,16.549999237060547,12.649999618530273,14.350000381469727,31426,0.0,0.0,14.574999904632568,15.462500023841859,,-1.5437360180793334,-5.739693567281106,,44.46403714751774,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-29,14.350000381469727,16.549999237060547,14.350000381469727,14.699999809265137,1566,0.0,0.0,14.599999904632568,15.447500014305115,,0.6849308581217077,-5.486325352890251,,47.68370316029308,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-11-30,16.700000762939453,16.700000762939453,14.899999618530273,15.0,18254,0.0,0.0,14.654999923706054,15.440000009536742,,2.3541458757421823,-5.0841974439496225,,50.3411933850512,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-01,16.950000762939453,17.100000381469727,15.300000190734863,15.300000190734863,3974,0.0,0.0,14.664999961853027,15.440000009536742,,4.330039076260585,-5.019430357545499,,52.9168326352004,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-02,15.25,15.25,14.699999809265137,14.699999809265137,296,0.0,0.0,14.614999961853027,15.425,,0.5815932099484795,-5.251215806463365,,47.59936787449812,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-05,14.800000190734863,14.800000190734863,13.800000190734863,14.5,1027,0.0,0.0,14.544999980926514,15.403749990463258,,-0.30938453754227874,-5.574941232287016,,45.942130759652066,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-06,15.0,15.0,15.0,15.0,8,0.0,0.0,14.630000019073487,15.41875,,2.529049763801335,-5.1155248053604385,,50.57505078839378,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-07,14.100000381469727,15.0,13.100000381469727,15.0,18655,0.0,0.0,14.730000019073486,15.411249995231628,,1.832993758159524,-4.420471904413508,,50.57505078839378,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-08,14.199999809265137,14.699999809265137,13.5,14.699999809265137,7600,0.0,0.0,14.805000019073486,15.397499990463256,,-0.7092212743875426,-3.8480270937278584,,47.728650785334096,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-09,13.800000190734863,14.899999618530273,13.550000190734863,14.5,6862,0.0,0.0,14.775,15.347499990463257,15.049999984105428,-1.861252115059224,-3.7302491664375372,1.9767442303788991,45.87499796762842,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-12,13.899999618530273,14.5,13.600000381469727,13.949999809265137,10426,0.0,0.0,14.734999942779542,15.234999966621398,15.057916649182637,-5.327452572533408,-3.281916803001736,1.1760147274315897,41.142818373598374,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-13,14.050000190734863,14.050000190734863,14.0,14.0,205,0.0,0.0,14.664999961853027,15.1224999666214,15.066666650772095,-4.534605956923575,-3.025293475140834,0.37057510558543255,41.73127462752358,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-14,13.5,14.0,13.0,13.850000381469727,6567,0.0,0.0,14.55,15.067499995231628,15.07458332379659,-4.8109939417888254,-3.4345445189673107,-0.04698855293585435,40.425485226868126,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-15,13.850000381469727,13.850000381469727,13.850000381469727,13.850000381469727,100,0.0,0.0,14.405000019073487,14.964999985694885,15.081666660308837,-3.8528263579930035,-3.7420645984410568,-0.773566192926078,40.425485226868126,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-16,13.850000381469727,13.850000381469727,13.850000381469727,13.850000381469727,0,0.0,0.0,14.320000076293946,14.866250014305114,15.089583333333334,-3.282120756425696,-3.674429916660471,-1.4800496083604198,40.425485226868126,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-19,13.850000381469727,13.850000381469727,13.850000381469727,13.850000381469727,0,0.0,0.0,14.255000114440918,14.75750000476837,15.099583339691161,-2.8411064869856406,-3.405047536270287,-2.2655150624162013,40.425485226868126,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-20,12.949999809265137,13.449999809265137,12.300000190734863,13.449999809265137,3658,0.0,0.0,14.100000095367431,14.678749990463256,15.106666668256123,-4.60993107592852,-3.9427737066973516,-2.8326346717641884,36.34623698864909,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-21,12.350000381469727,13.350000381469727,12.350000381469727,13.350000381469727,3141,0.0,0.0,13.935000133514404,14.642499995231628,15.110416674613953,-4.198060613129971,-4.831824223647761,-3.0966497447316743,35.38492413831429,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-22,13.100000381469727,13.350000381469727,12.5,13.350000381469727,7750,0.0,0.0,13.800000190734863,14.57000000476837,15.117916679382324,-3.2608681380110456,-5.284830568164085,-3.624286905623688,35.38492413831429,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-23,12.350000381469727,13.850000381469727,12.350000381469727,13.850000381469727,964,0.0,0.0,13.735000228881836,14.528750014305114,15.128750014305115,0.8372781264762535,-5.463304032636989,-3.9659588494268623,43.97726430721386,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-27,14.0,14.0,13.449999809265137,13.850000381469727,19147,0.0,0.0,13.725000286102295,14.500000023841858,15.144166684150695,0.9107474882459877,-5.3448257687259115,-4.253562931151553,43.97726430721386,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-28,13.850000381469727,14.0,12.550000190734863,12.550000190734863,18635,0.0,0.0,13.580000305175782,14.443750023841858,15.1475000222524,-7.584684030149481,-5.980093239223269,-4.645981167695657,31.390406583900116,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-29,13.25,13.949999809265137,13.199999809265137,13.949999809265137,3645,0.0,0.0,13.590000247955322,14.425000023841857,15.162500023841858,2.6490033461476825,-5.788559961916361,-4.863973611477916,48.488937740821726,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2022-12-30,13.949999809265137,13.949999809265137,13.0,13.949999809265137,4235,0.0,0.0,13.600000190734864,14.390000009536744,15.185416690508525,2.5735265707475024,-5.489922295193327,-5.238029994059682,48.48893774082172,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-02,12.550000190734863,14.75,12.550000190734863,14.0,2093,0.0,0.0,13.615000152587891,14.366250014305114,15.205000027020771,2.8277623437185904,-5.229269022668897,-5.516277614107967,49.015230660834405,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-03,13.800000190734863,15.199999809265137,13.199999809265137,14.050000190734863,6152,0.0,0.0,13.635000133514405,14.337500023841859,15.214583365122477,3.043638086958294,-4.899737675042828,-5.764754250788242,49.57011148073772,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-04,14.25,14.25,13.5,14.050000190734863,7052,0.0,0.0,13.695000171661377,14.308750033378601,15.225416700045267,2.5921870363176516,-4.289332473385201,-6.020634342729948,49.570111480737715,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-05,14.050000190734863,14.050000190734863,14.050000190734863,14.050000190734863,0,0.0,0.0,13.765000152587891,14.281250047683717,15.237916700045268,2.0704688339098234,-3.6148789032620856,-6.278198465008734,49.570111480737715,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-09,14.050000190734863,14.300000190734863,13.350000381469727,14.050000190734863,1605,0.0,0.0,13.835000133514404,14.261250042915345,15.252916701634724,1.554030033578644,-2.988867792923185,-6.5014887192893305,49.57011148073772,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-10,14.0,14.550000190734863,13.149999618530273,14.050000190734863,431,0.0,0.0,13.855000114440918,14.242500042915344,15.269583368301392,1.407434678334641,-2.7207296984856293,-6.726334966795509,49.57011148073772,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-11,14.050000190734863,14.600000381469727,14.050000190734863,14.600000381469727,156,0.0,0.0,13.930000114440919,14.241250061988831,15.285000038146972,4.809764978639402,-2.1855521544324694,-6.828589948009426,57.02278533419274,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-12,14.600000381469727,14.600000381469727,14.600000381469727,14.600000381469727,88,0.0,0.0,14.135000133514405,14.245000076293945,15.29208337465922,3.289708125667405,-0.7722003663769591,-6.84722462408501,57.02278533419274,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-13,14.600000381469727,14.75,13.699999809265137,14.5,5958,0.0,0.0,14.19000015258789,14.246250081062318,15.296666709582011,2.184635969546299,-0.3948402432525098,-6.86696421163246,55.299514223709075,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-16,14.550000190734863,14.550000190734863,13.300000190734863,14.5,2731,0.0,0.0,14.245000171661378,14.228750085830688,15.29375003973643,1.7901005634658549,0.11420599653986295,-6.963628613902049,55.29951422370909,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-17,14.449999809265137,14.449999809265137,13.75,14.399999618530273,515,0.0,0.0,14.285000133514405,14.208750081062316,15.291250038146973,0.8050366394191708,0.5366415203101946,-7.0792116693151454,53.426957466640395,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-18,13.550000190734863,13.899999618530273,13.149999618530273,13.600000381469727,2530,0.0,0.0,14.240000152587891,14.168750095367432,15.282083376248677,-4.494380366996378,0.5028676258730423,-7.2852192562408105,41.360666327023516,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-19,13.899999618530273,14.0,13.300000190734863,13.699999809265137,1389,0.0,0.0,14.205000114440917,14.157500100135803,15.259583377838135,-3.555088356968003,0.335511311807507,-7.222237006174854,43.09083404006551,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-20,13.100000381469727,14.25,13.100000381469727,13.75,2098,0.0,0.0,14.175000095367432,14.151250100135803,15.237500047683715,-2.998236984184059,0.16782966213989256,-7.128793726980402,43.980843396077056,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-23,13.75,14.25,13.649999618530273,13.649999618530273,1720,0.0,0.0,14.135000038146973,14.143750095367432,15.202500041325887,-3.4312021104195276,-0.06186518541022989,-6.964314705347084,42.54765699147154,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-24,14.0,14.0,14.0,14.0,25,0.0,0.0,14.130000019073487,14.12375009059906,15.17041670481364,-0.9200284423071846,0.044251196986179,-6.8993926441220825,48.83237672758648,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-25,14.0,14.199999809265137,14.0,14.199999809265137,612,0.0,0.0,14.089999961853028,14.120000076293945,15.138750036557516,0.7806944479057485,-0.21246539857520055,-6.729419257227069,52.059576038902755,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-26,14.25,14.25,14.0,14.0,1162,0.0,0.0,14.029999923706054,14.102500081062317,15.10000003973643,-0.21382696984455463,-0.5140943587273613,-6.605959973835371,48.74844767330672,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-27,14.0,14.0,13.449999809265137,14.0,1314,0.0,0.0,13.979999923706055,14.077500081062317,15.06250003973643,0.1430620629691892,-0.6925956795938725,-6.539418795522531,48.74844767330672,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-30,13.5,14.25,13.5,14.25,4860,0.0,0.0,13.954999923706055,14.051250076293945,15.035416706403096,2.1139382150250965,-0.6849935206140499,-6.545655829346093,53.07515967423303,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-01-31,13.75,14.199999809265137,13.75,14.199999809265137,195,0.0,0.0,13.934999942779541,14.038750076293946,15.002083365122477,1.9016854508342222,-0.7390268574522084,-6.4213300605176755,52.127324685708,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-01,14.199999809265137,14.199999809265137,14.199999809265137,14.199999809265137,0,0.0,0.0,13.994999885559082,14.031250071525573,14.976666696866353,1.4648083271339392,-0.2583532171524445,-6.3125970850282345,52.127324685708,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-02,14.0,14.0,14.0,14.0,70,0.0,0.0,14.024999904632569,14.006250071525574,14.95208335717519,-0.17825244065999174,0.1338676163230347,-6.3257625245630456,48.13920970991559,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-03,14.0,14.0,14.0,14.0,0,0.0,0.0,14.049999904632568,13.981250071525574,14.931250023841859,-0.35587120976478925,0.49172879932253355,-6.362494438170599,48.139209709915605,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-06,13.899999618530273,14.25,13.899999618530273,14.0,5980,0.0,0.0,14.084999942779541,13.963750076293945,14.903750030199687,-0.6034784744398617,0.8683187956180977,-6.307137143343162,48.139209709915605,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-07,14.0,14.0,14.0,14.0,9,0.0,0.0,14.084999942779541,13.951250076293945,14.88083336353302,-0.6034784744398617,0.9586944951468163,-6.246849652366324,48.139209709915605,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-08,13.899999618530273,14.0,13.899999618530273,14.0,1095,0.0,0.0,14.064999961853028,13.952500081062317,14.857916696866353,-0.462139794022894,0.806306254342237,-6.093832899164088,48.139209709915605,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-09,14.0,14.0,14.0,14.0,230,0.0,0.0,14.064999961853028,13.952500081062317,14.836250027020773,-0.462139794022894,0.806306254342237,-5.956693533399018,48.139209709915605,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-10,13.149999618530273,13.899999618530273,13.149999618530273,13.899999618530273,400,0.0,0.0,14.054999923706054,13.953750061988831,14.814583357175191,-1.1028125650456073,0.7256104005548735,-5.810715525586686,45.42833627719152,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-13,13.199999809265137,13.75,13.050000190734863,13.75,24987,0.0,0.0,14.004999923706055,13.951250052452087,14.787500023841858,-1.8207777586233387,0.3852692128080753,-5.655113914059081,41.64043442031905,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-14,13.050000190734863,13.649999618530273,13.050000190734863,13.449999809265137,589,0.0,0.0,13.929999923706054,13.941250038146972,14.762500015894572,-3.445801271140383,-0.08069659758009005,-5.563081977059252,35.300697549338395,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-15,13.100000381469727,13.949999809265137,13.050000190734863,13.75,3756,0.0,0.0,13.88499994277954,13.93875002861023,14.740000009536743,-0.9722718281302032,-0.3856162548317711,-5.435888605211037,44.414546345274886,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-16,13.5,13.5,13.5,13.5,80,0.0,0.0,13.834999942779541,13.9400000333786,14.719583344459533,-2.4213946090717346,-0.7532287686344485,-5.296232188354491,39.429933558824345,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-17,13.550000190734863,13.550000190734863,13.5,13.550000190734863,1255,0.0,0.0,13.789999961853027,13.94500002861023,14.707500012715657,-1.7403899331549684,-1.1115099780508875,-5.1844296001781,40.859510219560825,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-20,13.600000381469727,13.600000381469727,13.0,13.350000381469727,20500,0.0,0.0,13.725,13.94500002861023,14.699166679382325,-2.7322376577797676,-1.5776265913149294,-5.130676229625463,37.08870836441123,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-21,13.449999809265137,14.0,13.449999809265137,13.949999809265137,2560,0.0,0.0,13.719999980926513,13.947500014305115,14.701250012715658,1.6763835908044356,-1.631116925221502,-5.1271150259916425,51.538032556043284,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-22,13.949999809265137,13.949999809265137,12.5,13.800000190734863,40430,0.0,0.0,13.7,13.946250009536744,14.689583349227906,0.7299283995245548,-1.7657076946731454,-5.060275176084093,48.536706108548046,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-23,13.899999618530273,13.899999618530273,13.149999618530273,13.649999618530273,2420,0.0,0.0,13.664999961853027,13.973749995231628,14.677083349227905,-0.10977199681396707,-2.2095001948936988,-4.792051235665127,45.67235501391171,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-24,13.75,13.75,12.5,13.350000381469727,11322,0.0,0.0,13.610000038146973,13.958750009536743,14.662083355585734,-1.9103575014585077,-2.498432675930875,-4.79695367289701,40.52177299725216,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-27,13.800000190734863,13.800000190734863,11.800000190734863,12.600000381469727,37102,0.0,0.0,13.495000076293945,13.925000023841857,14.643333355585733,-6.632083658868765,-3.0879708927230376,-4.90553150912095,31.084065497204634,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-02-28,11.949999809265137,13.199999809265137,11.649999618530273,13.199999809265137,4873,0.0,0.0,13.470000076293946,13.905000019073487,14.629583350817363,-2.0044563140276948,-3.1283706737349997,-4.952863758101443,42.60143643239474,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-01,13.350000381469727,13.350000381469727,11.600000381469727,12.100000381469727,27754,0.0,0.0,13.305000114440919,13.856250023841858,14.60541668732961,-9.056743499485695,-3.9783484597378562,-5.129375488052076,32.03214207817166,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-02,12.5,13.5,12.25,13.100000381469727,10668,0.0,0.0,13.265000152587891,13.83250002861023,14.587916692097982,-1.2438731188855259,-4.102655881789695,-5.178372480677437,45.31477025272151,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-03,12.5,13.050000190734863,12.25,12.5,3065,0.0,0.0,13.160000133514405,13.793750023841858,14.565416693687439,-5.015198532054654,-4.594471331088683,-5.297937478026406,40.23420465534113,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-06,11.949999809265137,12.199999809265137,11.850000381469727,11.850000381469727,1323,0.0,0.0,13.010000133514405,13.73875002861023,14.537916700045267,-8.916216296235548,-5.304339139865285,-5.497119621221578,35.58019894915422,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-07,11.850000381469727,12.25,10.850000381469727,11.550000190734863,3616,0.0,0.0,12.770000171661376,13.67625002861023,14.50791670481364,-9.553641069119822,-6.626449904418327,-5.732502420057788,33.64576034551192,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-08,11.649999618530273,11.75,10.25,11.100000381469727,9879,0.0,0.0,12.500000190734863,13.58875002861023,14.474166711171469,-11.199998303222678,-8.012141187254716,-6.117220426084049,30.929364502209552,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-09,11.350000381469727,12.75,11.100000381469727,11.75,19357,0.0,0.0,12.310000228881837,13.517500019073486,14.44583338101705,-4.549148809664186,-8.932863240154179,-6.426305339804526,38.63595283349666,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-10,10.649999618530273,11.899999618530273,10.550000190734863,11.899999618530273,6964,0.0,0.0,12.16500015258789,13.452500009536744,14.418750047683716,-2.1783849628743512,-9.570710693448204,-6.701343978857547,40.291592908795785,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-13,10.800000190734863,11.050000190734863,10.550000190734863,10.649999618530273,5143,0.0,0.0,11.970000076293946,13.35625,14.390000041325887,-11.027572676276543,-10.379035460597498,-7.183808466692949,32.43738617923924,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-14,11.100000381469727,11.100000381469727,11.100000381469727,11.100000381469727,450,0.0,0.0,11.760000133514405,13.273750019073486,14.359583377838135,-5.612242725778279,-11.404086135296538,-7.561733026603476,37.184631987411436,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-15,10.199999809265137,10.5,9.65999984741211,10.399999618530273,2952,0.0,0.0,11.59000005722046,13.19375,14.322500038146973,-10.267475692968846,-12.155376165074678,-7.880956782270045,33.26865229109421,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-16,9.979999542236328,11.100000381469727,9.899999618530273,10.5,6131,0.0,0.0,11.330000019073486,13.113750004768372,14.289583373069764,-7.325684180725707,-13.602135049442651,-8.228604974707483,34.33258627830783,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-17,9.020000457763672,11.5,9.020000457763672,10.300000190734863,15179,0.0,0.0,11.110000038146973,13.027500009536743,14.253333377838135,-7.290727674445704,-14.718863711272842,-8.600327627271987,33.192754683353556,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-20,8.979999542236328,10.050000190734863,8.960000038146973,9.960000038146973,4759,0.0,0.0,10.921000003814697,12.93525002002716,14.193416714668274,-8.799560162366523,-15.57179036426722,-8.864438492395236,31.290862395216024,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-21,9.9399995803833,10.300000190734863,9.9399995803833,10.300000190734863,483,0.0,0.0,10.796000003814697,12.842750024795532,14.151333379745484,-4.5942924500238576,-15.937007393503483,-9.247067536567977,35.284213864739115,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-22,8.800000190734863,12.649999618530273,8.800000190734863,11.949999809265137,230,0.0,0.0,10.880999946594239,12.786500024795533,14.12300004164378,9.824463449294436,-14.902436745834713,-9.46328692846687,50.36171105297143,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-23,7.760000228881836,11.800000190734863,7.760000228881836,11.699999809265137,316,0.0,0.0,10.875999927520752,12.729000020027161,14.093000038464863,7.576313784807283,-14.557310783180085,-9.678563930425428,48.51730498583749,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-24,11.0,12.449999809265137,10.550000190734863,12.300000190734863,19019,0.0,0.0,10.91599998474121,12.686500024795532,14.068000038464865,12.67863876812257,-13.955780054340527,-9.82015929692936,52.969103720256626,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-27,12.5,12.5,11.100000381469727,11.899999618530273,10868,0.0,0.0,11.04099998474121,12.627750015258789,14.03966670036316,7.780089076860884,-12.565580001189625,-10.056625383192676,49.87287911067214,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-28,11.449999809265137,11.949999809265137,11.449999809265137,11.949999809265137,58,0.0,0.0,11.125999927520752,12.571500015258788,14.011750030517579,7.406074843719685,-11.498230807648616,-10.27887317517032,50.26423723012134,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-29,11.949999809265137,12.0,11.949999809265137,12.0,175,0.0,0.0,11.285999965667724,12.516500020027161,13.983833360671998,6.326422439343266,-9.831023468146544,-10.49306940950506,50.67892270612237,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-30,12.350000381469727,12.399999618530273,12.350000381469727,12.399999618530273,115,0.0,0.0,11.475999927520752,12.476500010490417,13.96716669400533,8.051583276797219,-8.019076520886713,-10.672649050252284,53.98435421575982,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-03-31,11.649999618530273,12.25,11.649999618530273,12.25,174,0.0,0.0,11.670999908447266,12.432750010490418,13.941750025749206,4.9610153036987334,-6.126963876860772,-10.823605447463883,52.561760861606594,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-03,10.850000381469727,12.300000190734863,10.850000381469727,12.100000381469727,994,0.0,0.0,11.88499994277954,12.385250020027161,13.91550002892812,1.8090066447228283,-4.039079360034784,-10.996730305916506,51.11127252127312,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-04,11.800000190734863,11.899999618530273,11.800000190734863,11.899999618530273,175,0.0,0.0,12.044999885559083,12.332750010490418,13.877166692415873,-1.2038212404024358,-2.3332194740554297,-11.129193128230613,49.163176097193265,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-05,11.899999618530273,11.899999618530273,11.899999618530273,11.899999618530273,0,0.0,0.0,12.039999866485596,12.280250000953675,13.822583349545797,-1.1627927699984921,-1.9563944907426258,-11.158068716892938,49.163176097193265,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-06,11.350000381469727,11.949999809265137,11.100000381469727,11.699999809265137,4703,0.0,0.0,12.039999866485596,12.222749996185303,13.765916681289672,-2.82392077234884,-1.4951637704832657,-11.210053938520542,47.08196730155585,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-11,11.699999809265137,11.949999809265137,11.699999809265137,11.899999618530273,698,0.0,0.0,11.999999809265137,12.172749996185303,13.731333351135254,-0.8333349360360353,-1.4191549729872195,-11.350560903986015,49.389262031020515,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-12,11.699999809265137,11.899999618530273,11.699999809265137,11.899999618530273,125,0.0,0.0,11.999999809265137,12.12649998664856,13.680916674931844,-0.8333349360360353,-1.0431713810472947,-11.361933744772466,49.389262031020515,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-13,11.699999809265137,11.949999809265137,11.5,11.949999809265137,331,0.0,0.0,11.999999809265137,12.08899998664856,13.632166679700216,-0.4166666732894109,-0.7362079368162504,-11.320039794918294,50.021088223509054,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-14,11.5,11.850000381469727,11.5,11.850000381469727,220,0.0,0.0,11.984999847412109,12.041499996185303,13.579250009854634,-1.1264035683031919,-0.46921188216661913,-11.324263214488036,48.711317234156894,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-17,11.5,11.800000190734863,10.699999809265137,11.649999618530273,1086,0.0,0.0,11.90999984741211,11.99524998664856,13.538000003496807,-2.183041412366858,-0.7106991461731832,-11.395701111314532,46.11077748150731,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-18,11.449999809265137,11.449999809265137,10.800000190734863,11.449999809265137,1213,0.0,0.0,11.829999828338623,11.942749977111816,13.510083333651226,-3.212172650782303,-0.9440886645812543,-11.601211612332985,43.60385381323268,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-19,11.449999809265137,11.449999809265137,11.449999809265137,11.449999809265137,0,0.0,0.0,11.764999771118164,11.895249962806702,13.470083332061767,-2.677432792020272,-1.0949764998280416,-11.691340954859687,43.60385381323268,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-20,11.449999809265137,11.449999809265137,10.399999618530273,11.25,2661,0.0,0.0,11.699999809265137,11.827749967575073,13.4346666653951,-3.846152278641795,-1.0800884247651026,-11.960971848740467,41.01756003653488,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-21,10.550000190734863,11.0,10.550000190734863,11.0,255,0.0,0.0,11.609999847412109,11.757749962806702,13.401333332061768,-5.254090055376519,-1.2566189607873253,-12.264327201853154,37.984671398619454,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-24,12.5,12.5,10.899999618530273,11.850000381469727,1752,0.0,0.0,11.624999904632569,11.712749981880188,13.376750000317891,1.9354879886708216,-0.7491842426703413,-12.439494035532986,51.197421132036816,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-25,11.850000381469727,11.850000381469727,10.649999618530273,11.100000381469727,1619,0.0,0.0,11.544999980926514,11.656499981880188,13.346750005086262,-3.8544789968988393,-0.9565478585081169,-12.66413188650378,42.577535468478494,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-26,10.899999618530273,11.050000190734863,10.899999618530273,11.050000190734863,590,0.0,0.0,11.460000038146973,11.617749977111817,13.310916670163472,-3.577660087673127,-1.3578355471208137,-12.72013592307209,42.069012216641916,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-27,11.050000190734863,11.050000190734863,10.0,10.050000190734863,3145,0.0,0.0,11.270000076293945,11.538999986648559,13.270083340009053,-10.825198556345258,-2.3312237686616335,-13.045007397514308,33.461325390698505,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-04-28,11.0,11.0,10.050000190734863,10.899999618530273,1159,0.0,0.0,11.175,11.508999967575074,13.234250005086263,-2.4608535254561725,-2.902076362117204,-13.036250915980366,43.95778321831646,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-02,10.199999809265137,10.899999618530273,10.199999809265137,10.899999618530273,1480,0.0,0.0,11.1,11.453999948501586,13.198416670163473,-1.801805238466002,-3.0906229273023254,-13.21686354701424,43.95778321831646,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-03,10.850000381469727,10.949999809265137,10.699999809265137,10.949999809265137,175,0.0,0.0,11.05,11.415249943733215,13.16341667175293,-0.9049791016729771,-3.199666634839922,-13.280493747273573,44.554485137164335,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-04,10.949999809265137,11.0,10.300000190734863,10.949999809265137,1298,0.0,0.0,11.0,11.392749929428101,13.130916666984557,-0.4545471884987571,-3.447367245493612,-13.237207893693967,44.55448513716433,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-05,10.949999809265137,10.949999809265137,10.949999809265137,10.949999809265137,0,0.0,0.0,10.969999980926513,11.377749919891357,13.09883333047231,-0.18231697079444345,-3.5837484725515742,-13.139211463796025,44.55448513716433,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-08,10.399999618530273,10.949999809265137,10.399999618530273,10.949999809265137,300,0.0,0.0,10.964999961853028,11.373999905586242,13.067999998728434,-0.13680029767511634,-3.595920055637921,-12.962963676974477,44.55448513716433,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-09,10.5,10.949999809265137,10.449999809265137,10.949999809265137,860,0.0,0.0,10.874999904632569,11.353999900817872,13.038833332061767,0.6896543015197573,-4.218777526594825,-12.921657853398457,44.55448513716433,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-10,10.899999618530273,10.899999618530273,10.899999618530273,10.899999618530273,55,0.0,0.0,10.854999828338624,11.328999900817871,13.009249997138976,0.4145535781048186,-4.183953364189088,-12.915810647736258,43.877763552289075,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-11,10.399999618530273,10.850000381469727,10.399999618530273,10.850000381469727,177,0.0,0.0,10.83499984741211,11.333999919891358,12.973000001907348,0.13844517091709316,-4.402682865768286,-12.633932642989414,43.17161944454962,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-12,10.100000381469727,10.75,10.100000381469727,10.75,36,0.0,0.0,10.904999828338623,11.325249910354614,12.935916670163472,-1.4213647939344987,-3.710735615924548,-12.451121948890103,41.72527727059043,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-15,10.75,10.75,10.75,10.75,0,0.0,0.0,10.889999866485596,11.333999919891358,12.898833338419596,-1.285581893498923,-3.9174171214394926,-12.13158878382691,41.72527727059043,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-16,10.100000381469727,10.699999809265137,10.100000381469727,10.699999809265137,190,0.0,0.0,10.869999885559082,11.338999915122987,12.870083340009053,-1.563938160843887,-4.136167502200899,-11.896453072113436,40.93011629197319,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-17,10.699999809265137,10.699999809265137,10.699999809265137,10.699999809265137,125,0.0,0.0,10.844999885559082,11.348999905586243,12.842583338419596,-1.3370223865748794,-4.4409201182483145,-11.629929847254177,40.93011629197319,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-19,10.699999809265137,10.699999809265137,10.699999809265137,10.699999809265137,69,0.0,0.0,10.819999885559081,11.367499899864196,12.815500005086262,-1.109058018143815,-4.816362605040846,-11.298818654343401,40.93011629197319,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-22,10.300000190734863,10.600000381469727,10.050000190734863,10.050000190734863,5544,0.0,0.0,10.729999923706055,11.361249899864196,12.77591667175293,-6.337369411055181,-5.556166634145481,-11.072917961468141,31.258153134596085,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-23,9.640000343322754,10.550000190734863,9.640000343322754,10.149999618530273,3783,0.0,0.0,10.649999904632569,11.316249895095826,12.740916665395101,-4.69483840919852,-5.887551058341267,-11.181823158523073,33.84805534952278,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-24,9.800000190734863,9.920000076293945,9.800000190734863,9.920000076293945,190,0.0,0.0,10.54699993133545,11.271749901771546,12.701083334287008,-5.94481709607932,-6.429791086139963,-11.253634000313399,30.958955138586916,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-25,9.920000076293945,10.0,9.619999885559082,10.0,195,0.0,0.0,10.456999969482421,11.214249897003175,12.659416667620341,-4.370278003405606,-6.752568691403213,-11.415745358263989,33.09797793109253,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-26,9.899999618530273,10.350000381469727,9.699999809265137,10.350000381469727,2278,0.0,0.0,10.406999969482422,11.17549991607666,12.618166669209797,-0.5477043161318512,-6.876649388084218,-11.433251683491061,41.619882215627285,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-29,10.350000381469727,10.350000381469727,9.4399995803833,9.760000228881836,3874,0.0,0.0,10.307999992370606,11.120749926567077,12.577000006039937,-5.316256925634149,-7.30840941090529,-11.578675986113657,33.80318456055272,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-30,10.25,10.350000381469727,10.0,10.350000381469727,16715,0.0,0.0,10.268000030517578,11.07949993610382,12.542416675885518,0.7986010002769224,-7.324336930964515,-11.663754901352872,44.93962322598266,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-05-31,9.779999732971191,9.819999694824219,9.760000228881836,9.819999694824219,402,0.0,0.0,10.180000019073486,11.014999938011169,12.49925000667572,-3.5363489545654407,-7.580571254078898,-11.874713025756172,38.649463248526345,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-01,8.539999961853027,9.979999542236328,8.539999961853027,9.979999542236328,1760,0.0,0.0,10.107999992370605,10.958249926567078,12.45741666952769,-1.2663281582003345,-7.7589938164773455,-12.034330894845569,41.31971552621757,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-02,9.380000114440918,9.979999542236328,9.380000114440918,9.979999542236328,507,0.0,0.0,10.035999965667724,10.905249905586242,12.418083333969117,-0.557995452600322,-7.970930950176966,-12.182503432269502,41.31971552621757,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-05,9.979999542236328,9.979999542236328,9.979999542236328,9.979999542236328,0,0.0,0.0,10.02899990081787,10.857249903678895,12.380416663487752,-0.4885866892624718,-7.628543233405523,-12.303033098239508,41.31971552621758,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-07,9.979999542236328,9.979999542236328,9.979999542236328,9.979999542236328,100,0.0,0.0,10.011999893188477,10.809249901771546,12.34733332792918,-0.3196199689726339,-7.375627502630001,-12.456806545252569,41.31971552621758,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-08,9.15999984741211,9.380000114440918,8.779999732971191,9.380000114440918,2383,0.0,0.0,9.957999897003173,10.75124990940094,12.308833328882853,-5.8043762657218165,-7.378212013322708,-12.654192138803452,33.881530900349006,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-09,8.84000015258789,9.0,8.84000015258789,8.960000038146973,1940,0.0,0.0,9.853999900817872,10.677749919891358,12.26808332602183,-9.072456582800433,-7.714640493114936,-12.963177408138534,29.83306306088363,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-12,9.119999885559082,9.119999885559082,8.0600004196167,8.760000228881836,6536,0.0,0.0,9.694999885559081,10.599249935150146,12.225666658083599,-9.644143039856537,-8.53126452459917,-13.3032968133322,28.110552304747046,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-13,8.65999984741211,8.65999984741211,8.640000343322754,8.65999984741211,339,0.0,0.0,9.58499984741211,10.51699993610382,12.182416653633117,-9.650495719619077,-8.861843627974611,-13.670659647259937,27.262947022379706,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-14,8.619999885559082,9.819999694824219,8.619999885559082,9.779999732971191,5761,0.0,0.0,9.527999782562256,10.465249919891358,12.148499981562297,2.644835811920723,-8.955831389632321,-13.855620564066326,46.661393351796974,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-15,8.699999809265137,9.100000381469727,8.0600004196167,8.9399995803833,20701,0.0,0.0,9.439999771118163,10.397499918937683,12.110916646321614,-5.2966123184093865,-9.208945951281605,-14.147704731370094,38.391617686359645,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-16,8.9399995803833,8.9399995803833,8.4399995803833,8.600000381469727,1318,0.0,0.0,9.301999855041505,10.326249933242797,12.071333312988282,-7.546758595048869,-9.918896838860872,-14.456426100568715,35.638418331713254,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-19,8.319999694824219,8.600000381469727,8.319999694824219,8.539999961853027,4564,0.0,0.0,9.157999897003174,10.253499937057494,12.031249976158142,-6.748197664343484,-10.684157085670224,-14.776104250377516,35.15923495814238,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-20,8.399999618530273,8.5600004196167,8.399999618530273,8.520000457763672,1340,0.0,0.0,9.011999988555909,10.185249948501587,11.986833310127258,-5.459382283810624,-11.519108179748525,-15.029685614327978,34.99035377009548,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-21,8.539999961853027,8.539999961853027,8.15999984741211,8.399999618530273,335,0.0,0.0,8.853999996185303,10.120249938964843,11.941416637102764,-5.1276301993520805,-12.512042196746965,-15.250842956768098,33.93702165823943,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-22,8.359999656677246,8.359999656677246,8.0,8.220000267028809,4125,0.0,0.0,8.738000011444091,10.029499936103822,11.905333304405213,-5.928127074122941,-12.877012143054476,-15.756244032305212,32.36325435592369,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-26,8.300000190734863,8.819999694824219,8.260000228881836,8.819999694824219,2580,0.0,0.0,8.723999977111816,9.972499918937682,11.862583303451538,1.1004094218737512,-12.519427946597187,-15.933151626121075,42.01578432031039,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-27,8.0600004196167,8.699999809265137,8.0600004196167,8.699999809265137,65,0.0,0.0,8.717999935150146,9.91374990940094,11.818833303451537,-0.20647081921204166,-12.061530552802184,-16.119047837778055,40.76282377498733,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-28,8.699999809265137,8.699999809265137,8.699999809265137,8.699999809265137,0,0.0,0.0,8.72199993133545,9.879999899864197,11.774666635195414,-0.25223712730464,-11.720647573535544,-16.091043543159923,40.76282377498732,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-29,8.65999984741211,9.5,8.65999984741211,8.800000190734863,536,0.0,0.0,8.623999977111817,9.827499914169312,11.730916635195415,2.0408188090231083,-12.246247240585435,-16.225643572603868,42.422294020306154,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-06-30,8.100000381469727,9.4399995803833,8.100000381469727,8.800000190734863,2095,0.0,0.0,8.610000038146973,9.774999928474426,11.687166635195414,2.2067381155178456,-11.918157533012616,-16.361251331546676,42.422294020306154,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-03,8.779999732971191,8.979999542236328,8.779999732971191,8.979999542236328,1261,0.0,0.0,8.647999954223632,9.725749921798705,11.64491662979126,3.8390331842052032,-11.081407359235815,-16.480725186840225,45.60345113800687,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-04,9.859999656677246,9.859999656677246,8.979999542236328,9.020000457763672,391,0.0,0.0,8.696000003814698,9.67749993801117,11.602999965349833,3.725856184531326,-10.142081534315993,-16.5948464456503,46.31332460988109,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-05,9.020000457763672,9.100000381469727,9.020000457763672,9.100000381469727,530,0.0,0.0,8.753999996185303,9.631249952316285,11.56174996693929,3.9524832697646604,-9.10837077714929,-16.697299458501103,47.78104096751439,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-06,9.020000457763672,9.180000305175781,9.020000457763672,9.180000305175781,208,0.0,0.0,8.832000064849854,9.58699996471405,11.51658329963684,3.9402200834544843,-7.875246715792751,-16.754824627401753,49.27447771901887,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-07,9.180000305175781,9.180000305175781,9.020000457763672,9.180000305175781,560,0.0,0.0,8.92800006866455,9.542749977111816,11.47141663233439,2.8225832725483504,-6.4420624025751145,-16.812802786590954,49.27447771901887,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-10,9.180000305175781,9.899999618530273,9.079999923706055,9.460000038146973,7444,0.0,0.0,8.992000102996826,9.506749987602234,11.429416632652282,5.204625553709379,-5.4145726486622,-16.822089060584705,54.55070164045647,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-11,9.399999618530273,9.460000038146973,9.399999618530273,9.460000038146973,704,0.0,0.0,9.06800012588501,9.471999979019165,11.387416632970174,4.322892664535601,-4.26520116162404,-16.820466974092017,54.55070164045647,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-12,9.0,9.84000015258789,9.0,9.600000381469727,3664,0.0,0.0,9.158000183105468,9.443249988555909,11.347416639328003,4.826383375484676,-3.020674087799535,-16.78061810273725,57.13610985742539,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-13,9.819999694824219,9.819999694824219,9.220000267028809,9.600000381469727,408,0.0,0.0,9.238000202178956,9.414499998092651,11.31408330599467,3.91859895397476,-1.8747654782458323,-16.789546766864802,57.13610985742539,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-14,9.800000190734863,9.800000190734863,9.779999732971191,9.779999732971191,804,0.0,0.0,9.336000156402587,9.391499996185303,11.28141663869222,4.755779446555721,-0.5909582048156186,-16.752476245093295,60.48766126040741,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-17,9.800000190734863,9.800000190734863,9.039999961853027,9.479999542236328,1247,0.0,0.0,9.386000156402588,9.360999989509583,11.24583330154419,1.001485023091751,0.26706726761052374,-16.76028144375745,53.04341018342266,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-18,9.479999542236328,9.859999656677246,9.020000457763672,9.859999656677246,428,0.0,0.0,9.470000076293946,9.339999985694885,11.214249968528748,4.1182637512282385,1.3918639271752593,-16.713110445136216,59.79333786563746,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-19,9.0,9.239999771118164,9.0,9.239999771118164,96,0.0,0.0,9.48400001525879,9.319749975204468,11.174583299954731,-2.5727566822865264,1.7623867645732432,-16.598680013041538,47.736227624372255,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-20,9.180000305175781,9.819999694824219,9.180000305175781,9.300000190734863,4111,0.0,0.0,9.496000003814697,9.298499989509583,11.133749969800313,-2.064024989480802,2.1239986506203112,-16.483664401201253,48.81196498966992,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-21,9.300000190734863,9.300000190734863,9.300000190734863,9.300000190734863,0,0.0,0.0,9.507999992370605,9.282999992370605,11.094583304723104,-2.1876293837047194,2.4237854161900225,-16.328538554316722,48.81196498966992,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-24,9.300000190734863,9.479999542236328,9.300000190734863,9.479999542236328,650,0.0,0.0,9.50999994277954,9.269999980926514,11.05691663424174,-0.31546162695815744,2.5889963575710735,-16.16107557310681,52.232720441566435,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-25,9.0600004196167,9.0600004196167,9.0600004196167,9.0600004196167,44,0.0,0.0,9.469999980926513,9.237749981880189,11.013666637738545,-4.32945683353318,2.514140342636267,-16.124663241332758,44.72266163175571,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-26,9.0600004196167,9.0600004196167,9.0600004196167,9.0600004196167,0,0.0,0.0,9.41599998474121,9.22024998664856,10.970833309491475,-3.7807940282648125,2.1230443683859805,-15.956703319230902,44.72266163175571,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-27,9.15999984741211,9.399999618530273,8.920000076293945,9.140000343322754,2712,0.0,0.0,9.369999980926513,9.189999985694886,10.92866664727529,-2.4546386133612015,1.9586506584528245,-15.909229530885943,46.4243449375731,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-28,9.140000343322754,9.15999984741211,9.039999961853027,9.15999984741211,1558,0.0,0.0,9.307999992370606,9.173499989509583,10.88833331267039,-1.5900316403073296,1.4661797897730524,-15.749272858549551,46.86472624336274,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-07-31,8.960000038146973,9.180000305175781,8.960000038146973,9.100000381469727,255,0.0,0.0,9.270000076293945,9.151500010490418,10.847499982515972,-1.8338694004863765,1.2948704110549067,-15.634938693331838,45.65235014509902,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-01,9.0,9.0,8.899999618530273,8.899999618530273,1750,0.0,0.0,9.174000072479249,9.124500012397766,10.804999979337056,-2.9867064724682026,0.5424961369305233,-15.552984453058723,41.77302519012984,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-02,9.0,9.0,9.0,9.0,7,0.0,0.0,9.150000095367432,9.100000023841858,10.76333331267039,-1.6393452874757395,0.5494513340063113,-15.45370045235418,44.32068587507899,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-03,8.859999656677246,9.0600004196167,8.84000015258789,9.0600004196167,429,0.0,0.0,9.126000118255615,9.077000045776368,10.72216664950053,-0.7232051039194024,0.5398267294495308,-15.343602254128355,45.85156390555504,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-04,8.720000267028809,8.9399995803833,8.720000267028809,8.9399995803833,193,0.0,0.0,9.09000005722046,9.066000032424927,10.679999979337056,-1.6501702518473438,0.2647256200054576,-15.112359082722726,43.28808489752711,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-07,8.579999923706055,8.920000076293945,8.579999923706055,8.920000076293945,30,0.0,0.0,9.03400011062622,9.0650000333786,10.638499983151753,-1.261899855393874,-0.34197377427727155,-14.790618529539994,42.85802652356513,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-08,8.979999542236328,9.180000305175781,8.739999771118164,9.15999984741211,1614,0.0,0.0,9.044000053405762,9.075000023841858,10.600249981880188,1.2826160252250822,-0.3415974694727526,-14.38881121337285,49.35978537318649,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-09,9.15999984741211,9.260000228881836,8.800000190734863,9.260000228881836,223,0.0,0.0,9.064000034332276,9.090000033378601,10.565333318710326,2.1624028442978607,-0.2860285913185147,-13.963906682612965,51.81970323203954,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-10,9.260000228881836,9.260000228881836,9.260000228881836,9.260000228881836,0,0.0,0.0,9.076000022888184,9.077000045776368,10.527916653951008,2.0273270772326275,-0.011017107889611178,-13.781611840839641,51.81970323203954,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-11,8.960000038146973,9.180000305175781,8.960000038146973,9.180000305175781,299,0.0,0.0,9.07800006866455,9.08300006389618,10.49191665649414,1.1235981024423538,-0.055047838780743714,-13.42859115951793,49.58493692119113,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-14,9.100000381469727,9.859999656677246,9.100000381469727,9.859999656677246,2294,0.0,0.0,9.153999996185302,9.114500045776367,10.46116665204366,7.712471714945942,0.433374844594345,-12.873005956789846,63.85413167579446,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-15,9.880000114440918,9.899999618530273,9.880000114440918,9.899999618530273,1313,0.0,0.0,9.253999996185303,9.148500037193298,10.432416645685832,6.980760996447642,1.1531940598250523,-12.306991295477818,64.49080368311806,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-16,9.899999618530273,9.899999618530273,9.899999618530273,9.899999618530273,0,0.0,0.0,9.34399995803833,9.183000016212464,10.398666644096375,5.950338859041152,1.7532390454276638,-11.690601011564112,64.49080368311805,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-17,9.899999618530273,9.899999618530273,9.899999618530273,9.899999618530273,0,0.0,0.0,9.427999877929688,9.220500016212464,10.366166639328004,5.006361335509827,2.25041875551625,-11.051979608055083,64.49080368311805,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-18,9.920000076293945,9.920000076293945,9.920000076293945,9.920000076293945,75,0.0,0.0,9.525999927520752,9.263000011444092,10.335083309809367,4.136050302025731,2.839252032297678,-10.37324292633157,64.87715393738085,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-21,9.020000457763672,9.84000015258789,9.020000457763672,9.84000015258789,55,0.0,0.0,9.617999935150147,9.288500022888183,10.305833307902018,2.3081744534684088,3.547396365936689,-9.871431592375874,61.97263225526259,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-22,9.84000015258789,9.899999618530273,9.84000015258789,9.899999618530273,3000,0.0,0.0,9.691999912261963,9.318500018119812,10.28333330154419,2.146096864953093,4.008154675279081,-9.3824954918022,63.29970545327568,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-23,8.899999618530273,9.899999618530273,8.899999618530273,9.880000114440918,480,0.0,0.0,9.75399990081787,9.348000025749206,10.255666637420655,1.2917799354548127,4.343173662284248,-8.850391142391214,62.51654614225374,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-24,9.199999809265137,9.859999656677246,9.199999809265137,9.859999656677246,288,0.0,0.0,9.813999843597411,9.374500012397766,10.23699996471405,0.4687162605759024,4.688248233168784,-8.425319481188222,61.694492393862234,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-25,9.880000114440918,9.880000114440918,9.880000114440918,9.880000114440918,151,0.0,0.0,9.883999824523926,9.401500010490418,10.210166629155477,-0.04046651309203623,5.132157777962274,-7.920209806918178,62.22935753313089,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-28,9.880000114440918,9.880000114440918,8.9399995803833,9.859999656677246,70,0.0,0.0,9.883999824523926,9.42350001335144,10.188166626294453,-0.24281837588797897,4.886717361065835,-7.505438819281769,61.307463293518715,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-29,9.100000381469727,9.859999656677246,8.920000076293945,9.640000343322754,3661,0.0,0.0,9.857999897003173,9.439000010490417,10.169749959309895,-2.211397402699216,4.4390283509596715,-7.185525226709362,52.15482410620604,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-30,9.640000343322754,9.640000343322754,9.640000343322754,9.640000343322754,0,0.0,0.0,9.831999969482421,9.452500009536744,10.153833293914795,-1.952803364072575,4.014810468794451,-6.907078972808837,52.154824106206036,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-08-31,8.920000076293945,9.520000457763672,8.579999923706055,9.5,6296,0.0,0.0,9.792000007629394,9.460500001907349,10.140499957402547,-2.9820262193819778,3.5040431864617188,-6.705783327761856,46.97863073951563,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-01,8.819999694824219,9.0,8.819999694824219,9.0,1069,0.0,0.0,9.7,9.455999994277954,10.117583290735881,-7.216494845360819,2.5803723124967735,-6.538945887045008,34.00018093022551,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-04,9.0,9.880000114440918,8.699999809265137,8.699999809265137,3336,0.0,0.0,9.585999965667725,9.436999988555907,10.090916625658672,-9.242647189399113,1.5788913562838496,-6.480250123561798,28.85018103682434,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-05,8.5,8.779999732971191,8.5,8.779999732971191,345,0.0,0.0,9.473999977111816,9.419999980926514,10.075333293279012,-7.325313973160823,0.5732483683082891,-6.504333834689654,31.81610834436158,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-06,8.779999732971191,9.380000114440918,8.5,9.300000190734863,2593,0.0,0.0,9.41599998474121,9.412499976158141,10.060333291689554,-1.2319434387672787,0.03718468623569427,-6.439481642885157,47.21792637235197,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-07,9.300000190734863,9.300000190734863,9.300000190734863,9.300000190734863,0,0.0,0.0,9.360000038146973,9.40499997138977,10.05116662979126,-0.6410240082006248,-0.4784681911715933,-6.428772720634006,47.21792637235197,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-08,9.300000190734863,9.300000190734863,9.300000190734863,9.300000190734863,0,0.0,0.0,9.302000045776367,9.392999982833862,10.041166631380717,-0.021499194062162504,-0.9688058897455692,-6.455093041890179,47.21792637235197,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-11,9.359999656677246,9.359999656677246,9.359999656677246,9.359999656677246,1,0.0,0.0,9.252000045776366,9.389999985694885,10.033333293596904,1.1673109637540755,-1.4696479246938616,-6.411959904816306,48.88196002393224,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-12,9.359999656677246,9.359999656677246,9.359999656677246,9.359999656677246,1020,0.0,0.0,9.223999977111816,9.377499985694886,10.028333290417988,1.4744111004216784,-1.636896921538038,-6.489944897872207,48.88196002393223,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-13,9.15999984741211,9.15999984741211,9.100000381469727,9.140000343322754,642,0.0,0.0,9.173999977111816,9.375,10.018666625022888,-0.37060860991810957,-2.1440002441406323,-6.424673553018017,43.10327253685797,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-14,9.239999771118164,9.359999656677246,9.020000457763672,9.359999656677246,220,0.0,0.0,9.15999994277954,9.37649998664856,9.997083290417988,2.18340300378885,-2.30896437025861,-6.207643627059166,49.528801662484035,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-15,9.359999656677246,9.359999656677246,8.4399995803833,9.239999771118164,48,0.0,0.0,9.183999919891358,9.374999976158142,9.976583290100098,0.6097544829624599,-2.0373339386935703,-6.029953306147568,46.44754042808381,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-18,9.239999771118164,9.239999771118164,9.239999771118164,9.239999771118164,0,0.0,0.0,9.23799991607666,9.368999981880188,9.951083286603291,0.021648138771073255,-1.3982289044389438,-5.8494466176032915,46.44754042808381,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-19,8.720000267028809,8.720000267028809,8.720000267028809,8.720000267028809,170,0.0,0.0,9.231999969482422,9.36049997806549,9.924583292007446,-5.545924005048685,-1.3727900099800647,-5.683697716520026,35.38448587824803,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-20,8.720000267028809,8.720000267028809,8.720000267028809,8.720000267028809,0,0.0,0.0,9.173999977111816,9.351999974250793,9.897666629155477,-4.948765110264765,-1.9033361594212082,-5.513083793884491,35.38448587824804,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-21,8.699999809265137,8.699999809265137,8.699999809265137,8.699999809265137,36,0.0,0.0,9.113999938964843,9.340999960899353,9.87016662756602,-4.542463599651157,-2.4301469102313757,-5.361273893682574,35.01248696969786,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-22,8.699999809265137,8.699999809265137,8.699999809265137,8.699999809265137,464,0.0,0.0,9.053999900817871,9.329499959945679,9.839333295822144,-3.9098751428167855,-2.9529991994277442,-5.181584163765892,35.01248696969786,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-25,8.479999542236328,8.899999618530273,8.479999542236328,8.899999618530273,1825,0.0,0.0,9.007999897003174,9.324499940872192,9.811416625976562,-1.1989373857434265,-3.3942843678050743,-4.9627561815611525,42.07492127381571,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-26,8.899999618530273,8.899999618530273,8.899999618530273,8.899999618530273,0,0.0,0.0,8.961999893188477,9.324499940872192,9.784749952952067,-0.6918129368125313,-3.8876084506662356,-4.703748325638279,42.07492127381571,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-27,8.600000381469727,8.899999618530273,8.600000381469727,8.899999618530273,180,0.0,0.0,8.937999820709228,9.32199993133545,9.759749952952067,-0.4251533110451486,-4.119288923564821,-4.48525857452126,42.07492127381571,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-28,8.880000114440918,9.300000190734863,8.880000114440918,8.899999618530273,15793,0.0,0.0,8.891999816894531,9.317999911308288,9.734749952952066,0.0899662820566321,-4.571797579615395,-4.281055431910699,42.07492127381571,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-09-29,8.899999618530273,9.199999809265137,8.800000190734863,9.199999809265137,813,0.0,0.0,8.88799982070923,9.324499917030334,9.713916619618734,3.510350977156197,-4.6812172256431435,-4.008853666727118,52.491527625315925,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-02,9.0,14.0,8.979999542236328,11.899999618530273,11880,0.0,0.0,9.15399980545044,9.398999905586242,9.713916619618734,29.997813758361907,-2.6066613745808045,-3.2419128798827628,82.6798291025102,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-03,12.5,15.0,12.0,12.5,20838,0.0,0.0,9.531999778747558,9.48249990940094,9.718916622797648,31.137225032986915,0.52201286390253,-2.4325418415685003,84.96602715435311,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-04,12.5,12.5,8.600000381469727,9.779999732971191,3234,0.0,0.0,9.637999725341796,9.495499897003175,9.700833288828532,1.4733348378919926,1.50070907150023,-2.116657257287569,51.669541903558134,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-05,10.899999618530273,13.449999809265137,10.550000190734863,11.300000190734863,2965,0.0,0.0,9.89799976348877,9.5464998960495,9.696249953905742,14.164482327204336,3.681976339671106,-1.5444121033196023,60.89254045370527,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-06,11.300000190734863,11.300000190734863,10.350000381469727,11.300000190734863,1706,0.0,0.0,10.157999801635743,9.599499893188476,9.693333292007447,11.24237459539253,5.818010465769808,-0.9680199369224238,60.89254045370527,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-09,10.800000190734863,11.25,10.350000381469727,11.050000190734863,372,0.0,0.0,10.3729998588562,9.629249906539917,9.689999961853028,6.526562624992782,7.723861770491071,-0.6269355578149431,58.75382488927315,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-10,11.25,11.300000190734863,10.399999618530273,11.300000190734863,1979,0.0,0.0,10.61299991607666,9.664249920845032,9.688749965031942,6.473195892685624,9.817109480842879,-0.2528710543190192,60.257082346519496,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-11,10.550000190734863,11.25,10.550000190734863,11.25,824,0.0,0.0,10.847999954223633,9.697999930381775,9.688749965031942,3.7057526500066906,11.858115406241163,0.09547119476936654,59.78775241863268,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-12,10.899999618530273,11.899999618530273,10.899999618530273,11.449999809265137,662,0.0,0.0,11.10299997329712,9.736749935150147,9.692499963442485,3.125279985612507,14.031889976086811,0.45653827056550517,61.093138426339166,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-13,11.800000190734863,12.0,10.649999618530273,10.699999809265137,1837,0.0,0.0,11.252999973297118,9.756249928474427,9.682916625340779,-4.914246559532811,15.341448361775791,0.7573472536335812,54.01222854206067,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-16,11.199999809265137,11.199999809265137,10.100000381469727,10.949999809265137,2506,0.0,0.0,11.157999992370605,9.783999919891357,9.681666620572408,-1.8641349995311969,14.043336914648147,1.0569802011309042,55.84918468615103,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-17,11.300000190734863,11.300000190734863,10.699999809265137,11.0,138,0.0,0.0,11.007999992370605,9.8114999294281,9.681249952316284,-0.07267434934729039,12.194874092123113,1.3453838889951755,56.22579398315169,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-18,11.0,11.0,10.949999809265137,10.949999809265137,28,0.0,0.0,11.125,9.838249921798706,9.68874994913737,-1.5730354223358496,13.079054592323674,1.54302643216267,55.713992811101754,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-19,10.199999809265137,10.199999809265137,10.199999809265137,10.199999809265137,30,0.0,0.0,11.014999961853027,9.846749925613404,9.682916617393493,-7.39900277267713,11.864321172621302,1.6919830531806443,48.5719061999298,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-20,10.100000381469727,10.100000381469727,10.100000381469727,10.100000381469727,328,0.0,0.0,10.894999980926514,9.852249932289123,9.676249957084655,-7.296921531423263,10.583877345822803,1.8188862005947417,47.69400517091033,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-23,10.25,10.350000381469727,10.0,10.050000190734863,3021,0.0,0.0,10.794999980926514,9.856999945640563,9.66874996026357,-6.901341283075285,9.516080353645515,1.9469940390501268,47.23430279411064,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-24,10.050000190734863,11.300000190734863,10.050000190734863,10.550000190734863,3526,0.0,0.0,10.719999980926513,9.879749941825867,9.665416630109151,-1.5858189411764985,8.504770303380369,2.217527913375586,52.196310126105075,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-25,10.550000190734863,10.550000190734863,10.550000190734863,10.550000190734863,0,0.0,0.0,10.65,9.90249993801117,9.662083299954732,-0.9389653452125547,7.548599511922435,2.488248451113685,52.196310126105075,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-26,10.350000381469727,10.350000381469727,9.239999771118164,10.0,2740,0.0,0.0,10.505000019073487,9.914999938011169,9.654166634877523,-4.807234823004087,5.9505807841756235,2.70176922564539,46.60515111434639,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-27,9.979999542236328,9.979999542236328,9.619999885559082,9.619999885559082,2014,0.0,0.0,10.39700002670288,9.930499935150147,9.643083302179972,-7.473310946890534,4.697649610786487,2.9805470300686845,43.16483979087096,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-30,9.979999542236328,9.979999542236328,9.979999542236328,9.979999542236328,511,0.0,0.0,10.3,9.962499928474426,9.635416634877522,-3.106800560812355,3.387704631855963,3.394594193394325,47.145446539901265,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-10-31,9.720000267028809,9.720000267028809,9.0,9.100000381469727,14772,0.0,0.0,10.110000038146973,9.970499944686889,9.62083330154419,-9.990105369597662,1.3991283710344065,3.6344735656793468,39.80625300472429,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-01,9.100000381469727,9.100000381469727,9.0,9.0,3774,0.0,0.0,9.915000057220459,9.962999939918518,9.606249968210856,-9.228442278768549,-0.48178142113340217,3.7137277594089766,39.06208988334361,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-02,8.9399995803833,8.9399995803833,8.899999618530273,8.899999618530273,3380,0.0,0.0,9.785000038146972,9.952999925613403,9.590833298365276,-9.044460052800316,-1.6879321684117987,3.776174770026057,38.29118580368104,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-03,8.760000228881836,8.760000228881836,8.760000228881836,8.760000228881836,625,0.0,0.0,9.651000022888184,9.939499926567077,9.574666635195415,-9.232201760369541,-2.9025595433404865,3.8104020251793944,37.18476810229409,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-06,8.920000076293945,9.800000190734863,8.619999885559082,9.100000381469727,10521,0.0,0.0,9.55600004196167,9.93299994468689,9.561333306630452,-4.771867501983976,-3.7954284186508422,3.887184204724872,41.59827327915702,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-07,9.0,9.0,9.0,9.0,1000,0.0,0.0,9.401000022888184,9.92399995326996,9.547166641553243,-4.265503902902747,-5.270051721528344,3.947069595251229,40.69266163436403,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-08,9.0,9.0,9.0,9.0,0,0.0,0.0,9.246000003814697,9.92049994468689,9.538416639963787,-2.660610033670802,-6.799051909006204,4.005730921023743,40.69266163436403,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-09,9.0,9.0,9.0,9.0,0,0.0,0.0,9.146000003814697,9.911499953269958,9.528833309809366,-1.596326303890246,-7.723351188663536,4.015881388822904,40.69266163436402,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-10,9.079999923706055,9.079999923706055,8.899999618530273,8.979999542236328,2431,0.0,0.0,9.081999969482421,9.904999947547912,9.520999972025553,-1.1231053467169962,-8.308934703924288,4.033189545747522,40.47256179853484,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-13,9.0,9.15999984741211,8.880000114440918,8.880000114440918,2100,0.0,0.0,8.972000026702881,9.895999956130982,9.511666639645894,-1.0254114131536878,-9.337105229630126,4.040651665430916,39.32720969487385,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-14,9.039999961853027,9.039999961853027,8.699999809265137,8.699999809265137,4276,0.0,0.0,8.931999969482423,9.89549994468689,9.497916634877523,-2.59740440002184,-9.736748831187567,4.18600546934042,37.2819995884693,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-15,8.84000015258789,9.0600004196167,8.84000015258789,8.979999542236328,4040,0.0,0.0,8.929999923706054,9.901999926567077,9.491416629155477,0.5599061473398464,-9.81619884941774,4.3258378960036525,42.30807377732665,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-16,8.979999542236328,9.0,8.84000015258789,8.84000015258789,2616,0.0,0.0,8.923999977111816,9.905499935150146,9.478833293914795,-0.9412799724267925,-9.908636257271889,4.501256937488949,40.5579610871374,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-17,8.960000038146973,9.0600004196167,8.960000038146973,9.039999961853027,1100,0.0,0.0,8.951999950408936,9.913999938964844,9.472333296140034,0.9830206873501061,-9.703449611442641,4.6627016703982385,44.11451893677976,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-20,9.039999961853027,9.0600004196167,9.0,9.0600004196167,1248,0.0,0.0,8.947999954223633,9.917999958992004,9.464666636784871,1.2516815597456499,-9.780197709004177,4.7897442097456615,44.47231927880447,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-21,9.039999961853027,9.0600004196167,9.0,9.0600004196167,1714,0.0,0.0,8.953999996185303,9.921999979019166,9.456999977429708,1.1838331860236333,-9.756097408594776,4.91699273235949,44.47231927880447,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-22,9.020000457763672,9.020000457763672,8.899999618530273,8.899999618530273,619,0.0,0.0,8.94399995803833,9.921999979019166,9.447999978065491,-0.49195370879346967,-9.856883925104745,5.016934822757353,41.97874236101826,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-23,9.140000343322754,9.140000343322754,8.899999618530273,8.899999618530273,2906,0.0,0.0,8.933999919891358,9.921999979019166,9.438999978701274,-0.3805719908882404,-9.957670441614699,5.117067500876812,41.97874236101826,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-24,8.199999809265137,8.4399995803833,8.199999809265137,8.359999656677246,7973,0.0,0.0,8.871999931335449,9.900999975204467,9.430499974886576,-5.770967973634036,-10.392890076214433,4.989131027738005,34.423777410245776,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-27,8.399999618530273,8.479999542236328,8.319999694824219,8.479999542236328,2660,0.0,0.0,8.83199987411499,9.815499973297118,9.426499970753987,-3.985511060867558,-10.019867575342284,4.126664231157015,37.13152239640535,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-28,8.479999542236328,8.479999542236328,8.300000190734863,8.300000190734863,5506,0.0,0.0,8.791999912261963,9.71049997806549,9.422666637102763,-5.595993248827502,-9.458833920789626,3.0546909070236303,34.809662709389656,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-29,8.4399995803833,8.4399995803833,8.220000267028809,8.4399995803833,449,0.0,0.0,8.73799991607666,9.676999974250794,9.420833301544189,-3.4103952684307277,-9.703421108532478,2.719150891509954,38.05414460510295,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-11-30,8.4399995803833,8.4399995803833,8.4399995803833,8.4399995803833,0,0.0,0.0,8.697999858856202,9.605499958992004,9.409666633605957,-2.9662023759428773,-9.44771333100953,2.081193022148548,38.05414460510295,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-01,8.199999809265137,8.300000190734863,8.199999809265137,8.300000190734863,268,0.0,0.0,8.623999881744385,9.530499958992005,9.404333305358886,-3.756953796988996,-9.511568974850459,1.3415799880383332,35.9774986550741,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-04,8.15999984741211,8.380000114440918,8.15999984741211,8.34000015258789,4455,0.0,0.0,8.551999855041505,9.46274995803833,9.402166636784871,-2.4789488546195155,-9.624581723446786,0.644354898119266,37.03475311070172,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-05,8.420000076293945,8.420000076293945,8.140000343322754,8.140000343322754,552,0.0,0.0,8.45999984741211,9.383749961853027,9.398833306630452,-3.7825001165602044,-9.844146723816824,-0.1604810329680429,34.01052267305394,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-06,7.840000152587891,7.840000152587891,7.820000171661377,7.820000171661377,7829,0.0,0.0,8.35199990272522,9.297999966144562,9.392999970912934,-6.369728654932742,-10.17423173654413,-1.0113915156239257,29.815343138698452,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-07,7.980000019073486,7.980000019073486,7.860000133514404,7.960000038146973,1940,0.0,0.0,8.25799994468689,9.210749971866608,9.389333307743073,-3.608620834777889,-10.343891975027068,-1.9019810035840603,33.67019807134065,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-08,7.800000190734863,7.800000190734863,7.739999771118164,7.739999771118164,304,0.0,0.0,8.195999956130981,9.136749970912934,9.385333303610484,-5.56369189181984,-10.29633094674642,-2.6486361715243607,30.806733707730686,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-11,8.100000381469727,8.100000381469727,8.100000381469727,8.100000381469727,1419,0.0,0.0,8.158000040054322,9.065499985218048,9.37933330933253,-0.710954379747824,-10.010478701047603,-3.3460088661335283,39.8250698479885,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-12,7.639999866485596,7.659999847412109,7.360000133514404,7.659999847412109,7834,0.0,0.0,8.094000005722046,8.981999981403352,9.370666642983755,-5.3619984927492075,-9.886439295478198,-4.14769489075162,33.993412468638596,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-13,7.539999961853027,7.860000133514404,7.539999961853027,7.860000133514404,1293,0.0,0.0,8.036000061035157,8.904749989509583,9.363666645685832,-2.190143431856585,-9.756028293864215,-4.901035817925968,38.408300927444515,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-14,7.860000133514404,7.860000133514404,7.860000133514404,7.860000133514404,0,0.0,0.0,7.978000116348267,8.846249997615814,9.355833311875662,-1.4790671987088673,-9.81489197684389,-5.446690821361867,38.408300927444515,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-15,7.880000114440918,7.900000095367432,7.619999885559082,7.679999828338623,2550,0.0,0.0,7.916000080108643,8.785749983787536,9.34649997552236,-2.9813068390820523,-9.899552175782995,-5.999571959593187,35.901838843594504,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-18,7.639999866485596,7.639999866485596,7.340000152587891,7.340000152587891,5726,0.0,0.0,7.816000080108642,8.717999982833863,9.332833313941956,-6.09007065816375,-10.34640863158178,-6.587852910537011,31.694479444687516,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-19,7.179999828338623,7.440000057220459,7.0,7.0,6721,0.0,0.0,7.7020000457763675,8.629249978065491,9.315999976793925,-9.114516250377475,-10.745429030866887,-7.371726067401483,28.142714649505905,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-20,7.059999942779541,7.239999771118164,6.519999980926514,6.760000228881836,17306,0.0,0.0,7.596000051498413,8.534499979019165,9.296499975522359,-11.005790112543043,-10.996542619109713,-8.196633125472344,25.933499095799675,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-21,6.5,7.159999847412109,6.5,7.159999847412109,3535,0.0,0.0,7.516000032424927,8.463499975204467,9.279666638374328,-4.736564442216469,-11.19513139428644,-8.795215334511655,35.080536593064664,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-22,6.900000095367432,7.0,6.699999809265137,6.900000095367432,4062,0.0,0.0,7.432000064849854,8.395499980449676,9.260666636625926,-7.158234187840659,-11.476385180674084,-9.342379875272872,32.289189661719234,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-27,6.800000190734863,6.900000095367432,6.800000190734863,6.900000095367432,48,0.0,0.0,7.312000036239624,8.318499994277953,9.23933330376943,-5.634572467590871,-12.09953668005855,-9.96644756949939,32.289189661719234,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-28,6.880000114440918,6.880000114440918,6.699999809265137,6.699999809265137,1753,0.0,0.0,7.216000032424927,8.25849997997284,9.21633330186208,-7.150779113652374,-12.623357148102107,-10.392780843719263,30.149021674129713,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2023-12-29,6.559999942779541,6.559999942779541,6.519999980926514,6.519999980926514,1457,0.0,0.0,7.082000017166138,8.196499979496002,9.190666631857555,-7.935611901685766,-13.597266700638656,-10.817133208982675,28.329111988794182,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-02,6.5,6.800000190734863,6.5,6.5,10973,0.0,0.0,6.946000003814698,8.136499989032746,9.164833295345307,-6.420961755971168,-14.631598191147704,-11.220425655039874,28.125957648766473,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-03,6.5,6.5,6.480000019073486,6.5,4764,0.0,0.0,6.828000020980835,8.0799999833107,9.137499964237213,-4.803749560236795,-15.495049070741086,-11.573187251057814,28.125957648766473,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-04,6.5,6.519999980926514,6.28000020980835,6.480000019073486,8611,0.0,0.0,6.742000007629395,8.014499974250793,9.112499968210857,-3.8860870403355627,-15.877471716385564,-12.049382691802027,27.89396577434026,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-05,6.380000114440918,6.380000114440918,6.380000114440918,6.380000114440918,101,0.0,0.0,6.6800000190734865,7.948999977111816,9.083499972025553,-4.4910165235924415,-15.964271753582354,-12.48967907092702,26.707766343784968,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-08,6.260000228881836,6.380000114440918,6.159999847412109,6.260000228881836,478,0.0,0.0,6.630000019073487,7.880499982833863,9.058666642506918,-5.580690635402993,-15.8682820440879,-13.005961099668042,25.316479465804363,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-09,6.28000020980835,6.5,6.28000020980835,6.480000019073486,848,0.0,0.0,6.562000036239624,7.817499983310699,9.035166641076406,-1.2496192732898563,-16.06012087945503,-13.476969558368213,32.28135702070453,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-10,6.340000152587891,6.340000152587891,6.320000171661377,6.320000171661377,340,0.0,0.0,6.504000043869018,7.750999999046326,9.010333307584126,-2.829026306374157,-16.088246101544794,-13.976545212570567,30.08397339107421,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-11,6.199999809265137,6.199999809265137,6.119999885559082,6.139999866485596,1594,0.0,0.0,6.428000020980835,7.6824999928474424,8.982499976952871,-4.480400646471899,-16.329319531852544,-14.472585443261277,27.791986895854365,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-12,6.039999961853027,6.079999923706055,5.920000076293945,6.079999923706055,4388,0.0,0.0,6.366000032424926,7.616999995708466,8.957666639486948,-4.492618712883183,-16.423788420485387,-14.966694985819093,27.052141812465123,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-15,6.079999923706055,6.079999923706055,6.079999923706055,6.079999923706055,0,0.0,0.0,6.322000026702881,7.544500005245209,8.932833302021027,-3.827904175492969,-16.203856818773968,-15.541914304632911,27.052141812465123,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-16,6.0,6.0,6.0,6.0,250,0.0,0.0,6.272000026702881,7.473500001430511,8.906666632493337,-4.336735101161477,-16.076804368738205,-16.09094277576688,25.98256655573958,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-17,6.0,6.239999771118164,6.0,6.239999771118164,2000,0.0,0.0,6.246000003814697,7.4034999966621395,8.882333298524221,-0.09606520481698341,-15.634497107709864,-16.64915346182502,34.366386549348704,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-18,6.300000190734863,6.300000190734863,6.300000190734863,6.300000190734863,495,0.0,0.0,6.228000020980835,7.334499990940094,8.85899996360143,1.1560720859260614,-15.08623588964562,-17.208488304831025,36.30868638300418,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-19,6.360000133514404,6.360000133514404,6.21999979019165,6.21999979019165,16,0.0,0.0,6.211999988555908,7.263499975204468,8.836666631698609,0.12877980763812336,-14.47649191489066,-17.802715911573806,34.8287259545756,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-22,6.059999942779541,6.21999979019165,6.059999942779541,6.21999979019165,1410,0.0,0.0,6.20799994468689,7.196499979496002,8.813499963283538,0.19329648214689174,-13.73584433579531,-18.346854150154336,34.8287259545756,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-23,6.119999885559082,6.179999828338623,5.78000020980835,5.900000095367432,8194,0.0,0.0,6.149999952316284,7.121499991416931,8.787166627248128,-4.0650383558896515,-13.641789514449643,-18.955673728390803,29.29025922427691,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-24,5.880000114440918,6.019999980926514,5.880000114440918,6.0,5037,0.0,0.0,6.117999935150147,7.0625,8.762666630744935,-1.9287338411397175,-13.373452245661637,-19.40238859230001,32.8821624230051,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-25,5.820000171661377,6.159999847412109,5.820000171661377,6.119999885559082,4917,0.0,0.0,6.115999937057495,7.003500008583069,8.739333295822144,0.0654013823209971,-12.672236316668911,-19.862307895602214,37.01678734165132,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-26,5.960000038146973,5.960000038146973,5.960000038146973,5.960000038146973,2,0.0,0.0,6.103999948501587,6.945000004768372,8.712666630744934,-2.3591073323970635,-12.10943204736303,-20.288468512486016,34.00856527579489,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-29,5.900000095367432,5.900000095367432,5.900000095367432,5.900000095367432,765,0.0,0.0,6.085999965667725,6.881500017642975,8.684666629632314,-3.0561924309818167,-11.559980381250105,-20.76264626942486,32.92790010355645,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-30,6.760000228881836,10.600000381469727,6.739999771118164,9.079999923706055,83566,0.0,0.0,6.39399995803833,6.8975000262260435,8.683166627089182,42.008132363075354,-7.299747245716248,-20.56469347590695,76.16225410512294,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-01-31,9.119999885559082,9.460000038146973,8.680000305175781,8.720000267028809,6598,0.0,0.0,6.642000007629394,6.908000028133392,8.679333293437958,31.285761171522136,-3.8506082718687162,-20.408632845610263,70.61303796689722,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-01,8.739999771118164,8.739999771118164,8.380000114440918,8.380000114440918,3472,0.0,0.0,6.85,6.909000027179718,8.666999963919322,22.335768094028005,-0.8539589947548785,-20.283834591648194,65.74121721228472,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-02,7.619999885559082,8.800000190734863,7.579999923706055,8.359999656677246,13899,0.0,0.0,7.063999986648559,6.9145000100135805,8.65416663090388,18.3465412298728,2.1621227336535225,-20.102069847811574,65.45513186538273,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-05,8.619999885559082,8.699999809265137,8.4399995803833,8.5,1294,0.0,0.0,7.292000007629395,6.931500005722046,8.642499967416127,16.56609971347658,5.200894490510732,-19.797511925309543,66.55236065241587,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-06,8.699999809265137,8.920000076293945,8.579999923706055,8.859999656677246,6729,0.0,0.0,7.587999963760376,6.953999996185303,8.633833301067352,16.76330652335041,9.117054471136923,-19.456401882051402,69.25647461281329,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-07,8.600000381469727,8.600000381469727,8.4399995803833,8.4399995803833,1479,0.0,0.0,7.831999921798706,6.971499991416931,8.62149996360143,7.763019211636565,12.343110255198921,-19.13820076727402,62.87035034734132,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-08,8.359999656677246,8.920000076293945,8.359999656677246,8.720000267028809,10557,0.0,0.0,8.091999959945678,6.986999988555908,8.612166631221772,7.760755192679788,15.815084774576537,-18.870589855683136,65.17578456951897,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-09,8.720000267028809,8.920000076293945,8.720000267028809,8.859999656677246,3046,0.0,0.0,8.381999921798705,7.016999983787537,8.603499964872997,5.702693144095927,19.452756750248533,-18.440169553820407,66.3024172933774,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-12,8.859999656677246,8.920000076293945,8.319999694824219,8.899999618530273,5687,0.0,0.0,8.68199987411499,7.042999970912933,8.595333294073741,2.5109392717827697,23.271331960400456,-18.060187662892627,66.63455339299234,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-13,8.920000076293945,8.920000076293945,8.359999656677246,8.920000076293945,1151,0.0,0.0,8.66599988937378,7.069499969482422,8.587499964237214,2.930996886252217,22.58292562109229,-17.6768559077325,66.81070249577922,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-14,8.739999771118164,8.920000076293945,8.739999771118164,8.920000076293945,372,0.0,0.0,8.685999870300293,7.100499975681305,8.579499963919321,2.6939927410517273,22.329412013931552,-17.238766763306497,66.81070249577922,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-15,8.420000076293945,8.920000076293945,8.420000076293945,8.920000076293945,1800,0.0,0.0,8.739999866485595,7.139999973773956,8.571666634082794,2.059498999520341,22.40896216510677,-16.702313813934648,66.81070249577921,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-16,8.460000038146973,8.779999732971191,8.460000038146973,8.779999732971191,1638,0.0,0.0,8.781999874114991,7.184499967098236,8.564499962329865,-0.02277546313448454,22.23536661330062,-16.113024710157365,63.86304947051452,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-19,8.779999732971191,9.760000228881836,8.779999732971191,9.0,18744,0.0,0.0,8.83199987411499,7.24049996137619,8.559166626135509,1.9021753654841913,21.98052511882489,-15.406484326788966,66.3737103866851,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-20,9.0,9.0,9.0,9.0,100,0.0,0.0,8.845999908447265,7.286499965190887,8.55499995946884,1.7409008947160014,21.40259316141399,-14.827586210260035,66.3737103866851,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-21,9.119999885559082,9.140000343322754,8.479999542236328,8.5,19891,0.0,0.0,8.851999950408935,7.326499962806702,8.550833292802174,-3.9765019473669736,20.821674678857576,-14.318292592911128,56.10023460898494,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-22,8.920000076293945,8.9399995803833,8.739999771118164,8.739999771118164,6098,0.0,0.0,8.853999900817872,7.37249995470047,8.551166625817617,-1.287555127363139,20.094946832422085,-13.78369435064597,59.35246307045435,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-23,8.960000038146973,8.960000038146973,8.739999771118164,8.760000228881836,4836,0.0,0.0,8.84399995803833,7.4239999651908875,8.55099996328354,-0.9497934142361257,19.12715516575209,-13.179745093343323,59.62092886691347,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-26,8.760000228881836,8.760000228881836,8.760000228881836,8.760000228881836,0,0.0,0.0,8.830000019073486,7.479999971389771,8.54649996360143,-0.7927496040820504,18.048129048761048,-12.478792450169797,59.62092886691347,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-27,8.760000228881836,8.760000228881836,8.760000228881836,8.760000228881836,1050,0.0,0.0,8.814000034332276,7.536499977111816,8.541999963919322,-0.6126594649432706,16.950840059712053,-11.771247846577516,59.62092886691347,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-28,8.760000228881836,8.760000228881836,8.5,8.539999961853027,10714,0.0,0.0,8.776000022888184,7.587499976158142,8.535666628678639,-2.6891529218283727,15.66392158767198,-11.108290585468628,54.66106098628089,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-02-29,8.479999542236328,8.479999542236328,6.300000190734863,6.480000019073486,75846,0.0,0.0,8.532000017166137,7.587499976158142,8.511666631698608,-24.050632840647985,12.44810601615624,-10.857646281619433,29.72518528963397,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-01,6.460000038146973,6.980000019073486,6.199999809265137,6.539999961853027,61899,0.0,0.0,8.30800004005432,7.591499972343445,8.48816663424174,-21.280694146334326,9.43818837280055,-10.56372595562735,30.71657459508937,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-04,6.78000020980835,10.199999809265137,6.460000038146973,7.119999885559082,97755,0.0,0.0,8.12000002861023,7.612999963760376,8.47133329709371,-12.315272654282266,6.659661989534882,-10.132210635931477,39.58864324391606,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-05,7.159999847412109,7.900000095367432,7.139999866485596,7.300000190734863,21226,0.0,0.0,7.950000047683716,7.63349996805191,8.454166634877522,-8.17609878050547,4.146198741814854,-9.707244986631387,42.068027540337454,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-06,7.5,8.220000267028809,7.079999923706055,7.880000114440918,21153,0.0,0.0,7.888000059127807,7.672499966621399,8.442833304405212,-0.10141917630479888,2.8087337040589686,-9.12410928902122,49.29003519243224,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-07,7.099999904632568,7.5,6.760000228881836,7.0,42291,0.0,0.0,7.714000082015991,7.693999969959259,8.424166639645895,-9.255899331406187,0.25994427001326553,-8.667524052175299,40.94896088928619,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-08,6.800000190734863,6.980000019073486,6.699999809265137,6.800000190734863,14290,0.0,0.0,7.518000078201294,7.71199997663498,8.408166639010112,-9.55041074751112,-2.515558856605891,-8.279648730381153,39.32037002568655,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-11,6.800000190734863,6.800000190734863,6.559999942779541,6.559999942779541,3893,0.0,0.0,7.298000049591065,7.723999977111816,8.390166636308034,-10.11236094541924,-5.515276136497906,-7.939850161180524,37.39822189016464,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-12,6.659999847412109,6.659999847412109,6.559999942779541,6.639999866485596,3978,0.0,0.0,7.08600001335144,7.739999973773957,8.372999970118205,-6.294103105073259,-8.449611920394254,-7.560014315099915,38.47782348093041,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-13,6.579999923706055,6.619999885559082,6.579999923706055,6.619999885559082,196,0.0,0.0,6.894000005722046,7.749499976634979,8.355666637420654,-3.9744722938140833,-11.039421556130025,-7.254557740144539,38.29999543299012,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-14,6.519999980926514,7.340000152587891,6.519999980926514,6.659999847412109,17311,0.0,0.0,6.911999988555908,7.75849996805191,8.336999972661337,-3.6458353813806625,-10.910613945759295,-6.938946941423077,38.90811359996688,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-15,6.679999828338623,6.679999828338623,6.659999847412109,6.659999847412109,1104,0.0,0.0,6.923999977111817,7.769499969482422,8.318333307902018,-3.8128268424666953,-10.882296102601437,-6.597876258435452,38.90811359996689,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-18,6.699999809265137,6.900000095367432,6.699999809265137,6.699999809265137,3543,0.0,0.0,6.881999969482422,7.781499969959259,8.299999976158142,-2.6445824037249004,-11.55946801965414,-6.246988044437128,39.598543450728364,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-19,6.619999885559082,6.639999866485596,6.599999904632568,6.599999904632568,1588,0.0,0.0,6.811999940872193,7.7989999651908875,8.28083331187566,-3.112155579562151,-12.655469018129903,-5.818657718828481,38.42925233100402,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-20,6.599999904632568,6.599999904632568,6.519999980926514,6.599999904632568,4092,0.0,0.0,6.683999919891358,7.813999962806702,8.259166646003724,-1.2567327388620728,-14.461224063142438,-5.3899709532125755,38.42925233100402,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-21,6.639999866485596,6.840000152587891,6.519999980926514,6.619999885559082,31131,0.0,0.0,6.645999908447266,7.826499962806702,8.215166648228964,-0.3912131093341844,-15.08337136612074,-4.731087049902403,38.84809679552746,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-22,6.739999771118164,6.840000152587891,6.559999942779541,6.840000152587891,9150,0.0,0.0,6.649999904632568,7.848499965667725,8.167999982833862,2.857146626768569,-15.270434685326423,-3.9116064867483993,43.40854495236884,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-25,6.840000152587891,6.840000152587891,6.840000152587891,6.840000152587891,0,0.0,0.0,6.6779999256134035,7.871999967098236,8.143499986330669,2.4258794366429512,-15.16768351721631,-3.3339475617137766,43.40854495236884,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-26,6.277234077453613,6.546807765960693,6.277234077453613,6.546807765960693,7312,0.0,0.0,6.668680715560913,7.808670163154602,8.10389004945755,-1.827542130122339,-14.599021648689387,-3.642940421220421,38.92218972458209,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-27,6.546807765960693,6.546807765960693,6.373509883880615,6.508296966552734,1677,0.0,0.0,6.657510423660279,7.7533775806427006,8.063959189256032,-2.241280112416365,-14.13406151814913,-3.8514779319212433,38.361365180569145,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-03-28,6.354255199432373,6.489041805267334,6.354255199432373,6.489041805267334,269,0.0,0.0,6.640414619445801,7.706103622913361,8.02595120271047,-2.279568714507476,-13.82915485718146,-3.9851672620323493,38.06602901554079,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-02,6.450531005859375,8.66489315032959,6.450531005859375,7.2207441329956055,23627,0.0,0.0,6.696489048004151,7.677622234821319,7.991957402229309,7.828805232612246,-12.779128183297528,-3.9331436791731096,52.90410500377569,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-03,6.402392864227295,7.509573936462402,6.402392864227295,6.787499904632568,34390,0.0,0.0,6.7052390575408936,7.634809732437134,7.95476990143458,1.2268145309325253,-12.17542686030381,-4.022242917922038,45.893116601389245,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-04,7.199999809265137,7.300000190734863,7.050000190734863,7.150000095367432,12760,0.0,0.0,6.76023907661438,7.592059743404389,7.918936570485433,5.765491639213582,-10.956455756458631,-4.127786908905704,51.66493099594465,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-05,7.400000095367432,7.400000095367432,6.949999809265137,7.099999904632568,15977,0.0,0.0,6.81023907661438,7.55855975151062,7.888936571280161,4.254782023926232,-9.900307723924309,-4.187849867779202,50.85904036936647,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-08,7.099999904632568,7.300000190734863,6.900000095367432,7.099999904632568,4893,0.0,0.0,6.858239078521729,7.518059742450714,7.856853238741556,3.5251151694022056,-8.776475401004182,-4.312076170906142,50.85904036936647,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-09,7.150000095367432,7.300000190734863,6.699999809265137,7.300000190734863,91839,0.0,0.0,6.904239082336426,7.4790597558021545,7.826019906997681,5.7321466374323435,-7.6857344670871255,-4.433417692757081,54.175012904135095,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-10,7.050000190734863,7.300000190734863,6.949999809265137,6.949999809265137,16952,0.0,0.0,6.915239048004151,7.430309760570526,7.792686573664347,0.5026689752831995,-6.932022071268619,-4.6502167085544786,48.06279412863414,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-11,6.949999809265137,7.25,6.949999809265137,6.949999809265137,13349,0.0,0.0,6.955558252334595,7.381059753894806,7.765603240331014,-0.07991368726719418,-5.764775191471442,-4.951881708803565,48.06279412863414,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-12,7.099999904632568,8.699999809265137,7.0,7.0,51014,0.0,0.0,7.004728555679321,7.333059751987458,7.739769903818766,-0.06750519512262115,-4.477410622750615,-5.25480934039964,49.015826733083685,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-15,7.0,7.25,7.0,7.150000095367432,2467,0.0,0.0,7.070824384689331,7.288809752464294,7.715603236357371,1.119752186881379,-2.990685381810984,-5.531563389391845,51.86918900168109,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-16,7.25,7.25,7.0,7.25,4394,0.0,0.0,7.073749971389771,7.250559759140015,7.6881032347679135,2.4916067053978965,-2.4385674158103274,-5.691175863107502,53.72840042738029,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-17,7.199999809265137,7.199999809265137,7.0,7.0,272,0.0,0.0,7.094999980926514,7.200559759140015,7.658519899845123,-1.3389708411825547,-1.4659940580245734,-5.979747349280495,48.66705716720285,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-18,7.0,7.199999809265137,6.099999904632568,6.550000190734863,93093,0.0,0.0,7.034999990463257,7.139309763908386,7.629769901434581,-6.894098086508406,-1.4610624401318184,-6.428242841687483,41.15232857558444,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-19,6.599999904632568,6.75,6.5,6.699999809265137,11692,0.0,0.0,6.994999980926513,7.094309759140015,7.605436567465464,-4.217300535607761,-1.399851170659061,-6.7205452808843,44.24291426035878,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-22,6.199999809265137,6.550000190734863,6.199999809265137,6.5,10822,0.0,0.0,6.934999990463257,7.038309764862061,7.576436571280161,-6.27253051278229,-1.4678207957621594,-7.1026372537449385,41.14046417038514,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-23,6.599999904632568,6.599999904632568,6.199999809265137,6.199999809265137,15233,0.0,0.0,6.8249999523162845,6.974309754371643,7.552269899845124,-9.157511317476768,-2.1408541821901186,-7.652800457850861,36.95441745372816,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-24,6.349999904632568,6.599999904632568,6.199999809265137,6.25,25637,0.0,0.0,6.75499997138977,6.911559748649597,7.5293532331784565,-7.475943353496,-2.265187352108415,-8.205133500796892,38.08516183682958,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-25,6.199999809265137,6.199999809265137,5.5,6.150000095367432,16186,0.0,0.0,6.675,6.846309745311737,7.506436570485433,-7.8651671106002725,-2.5022201986851127,-8.794143785471379,36.668659111729724,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-26,5.800000190734863,6.150000095367432,5.75,5.849999904632568,8091,0.0,0.0,6.559999990463257,6.779059743881225,7.482186567783356,-10.823172055836379,-3.2314179501912745,-9.39734417916869,32.735130496346756,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-29,5.849999904632568,5.949999809265137,5.75,5.949999809265137,7270,0.0,0.0,6.439999961853028,6.765809738636017,7.455936563014984,-7.608698066620791,-4.815532646779283,-9.256071568558223,35.229314649374714,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-04-30,6.150000095367432,7.0,6.150000095367432,7.0,8649,0.0,0.0,6.414999961853027,6.7773097395896915,7.439269896348318,9.119252402582873,-5.345923259493802,-8.898187133707298,54.36402897723212,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-02,6.900000095367432,6.900000095367432,6.449999809265137,6.650000095367432,4112,0.0,0.0,6.37999997138977,6.7655597448349,7.419686563809713,4.2319768838313445,-5.698859931574497,-8.816097733364966,49.15155408768375,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-03,6.5,6.599999904632568,6.5,6.599999904632568,645,0.0,0.0,6.384999942779541,6.748059737682342,7.399686563014984,3.3672664648362174,-5.380210149525085,-8.806140905880989,48.43706017143614,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-06,6.400000095367432,6.800000190734863,6.300000190734863,6.650000095367432,7700,0.0,0.0,6.37999997138977,6.717309737205506,7.380269900957743,4.2319768838313445,-5.021500853942476,-8.982871529755364,49.23182297605642,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-07,6.800000190734863,6.849999904632568,6.300000190734863,6.599999904632568,26432,0.0,0.0,6.389999961853027,6.70730973482132,7.361269899209341,3.286384100676016,-4.7308054274124824,-8.883795504607997,48.427962375950806,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-08,6.300000190734863,6.550000190734863,6.300000190734863,6.550000190734863,37861,0.0,0.0,6.425,6.701059734821319,7.3433532357215885,1.945528260464801,-4.119642948216167,-8.746596824129963,47.5911244898321,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-10,6.5,6.550000190734863,6.050000190734863,6.550000190734863,22335,0.0,0.0,6.455000019073486,6.700809741020203,7.323103241125742,1.4717299981513106,-3.6683584737818915,-8.497674819205162,47.5911244898321,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-13,6.550000190734863,6.550000190734863,6.300000190734863,6.300000190734863,19919,0.0,0.0,6.4700000286102295,6.6923097491264345,7.301936574776968,-2.627509074553784,-3.321868366078299,-8.348837591336569,43.25661893133298,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-14,6.150000095367432,6.849999904632568,6.150000095367432,6.849999904632568,102444,0.0,0.0,6.570000028610229,6.698059749603272,7.2836865743001304,4.261794137032422,-1.911892783587479,-8.040252950520872,53.327773385474885,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-15,6.75,6.75,6.550000190734863,6.699999809265137,919,0.0,0.0,6.645000028610229,6.6990597486495975,7.264019902547201,0.8276866880075898,-0.8069747407502317,-7.777513848764296,50.68559375523751,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-16,6.5,6.599999904632568,6.5,6.599999904632568,8000,0.0,0.0,6.605000019073486,6.697559750080108,7.243519898255666,-0.07570195952277012,-1.3819918665976048,-7.537221624904107,48.94456441071726,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-17,6.599999904632568,6.599999904632568,6.400000095367432,6.5,11319,0.0,0.0,6.590000009536743,6.69255975484848,7.223519901434581,-1.3657057573065094,-1.5324442226673705,-7.350435159466412,47.19860013192332,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-20,6.550000190734863,6.650000095367432,6.400000095367432,6.449999809265137,8610,0.0,0.0,6.575,6.688809752464294,7.203103236357371,-1.9011435853211172,-1.7014948350469141,-7.139887726406595,46.30908398618806,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-21,6.349999904632568,6.400000095367432,6.25,6.300000190734863,14435,0.0,0.0,6.540000009536743,6.681309759616852,7.185936574141184,-3.6697219946774884,-2.1150007283633623,-7.022422328917398,43.65126887208249,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-22,6.349999904632568,6.349999904632568,6.25,6.25,4307,0.0,0.0,6.505000019073487,6.672059762477875,7.167353244622548,-3.9200617728792344,-2.503870608951877,-6.910409815733272,42.77008830100727,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-23,6.150000095367432,6.449999809265137,6.150000095367432,6.400000095367432,6009,0.0,0.0,6.490000009536743,6.661059761047364,7.151519910494486,-1.386747519831448,-2.5680560998858777,-6.858124644628309,46.274029937555774,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-24,6.349999904632568,6.400000095367432,6.199999809265137,6.349999904632568,15229,0.0,0.0,6.469999980926514,6.648809754848481,7.1341032465298975,-1.8547152495781198,-2.6893501320529456,-6.80244559002519,45.278867101293734,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-27,6.5,6.5,6.150000095367432,6.300000190734863,14797,0.0,0.0,6.469999980926514,6.642639565467834,7.116269918282827,-2.6275083569212985,-2.5989605914913376,-6.655598484230634,44.25394845740582,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-28,6.449999809265137,6.449999809265137,6.300000190734863,6.449999809265137,12228,0.0,0.0,6.429999971389771,6.641182136535645,7.100853248437246,0.31103947067426063,-3.1798881705725432,-6.473463058862191,48.05288951399604,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-29,6.300000190734863,6.849999904632568,6.300000190734863,6.699999809265137,11664,0.0,0.0,6.429999971389771,6.64645608663559,7.087186578909556,4.199064371333247,-3.256714742779386,-6.218694645143338,53.714360072102394,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-30,6.699999809265137,7.050000190734863,6.449999809265137,6.699999809265137,9633,0.0,0.0,6.439999961853028,6.633437478542328,7.075186574459076,4.03726473528266,-2.916097684119692,-6.243638825178563,53.71436007210239,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-05-31,7.0,7.099999904632568,6.650000095367432,6.849999904632568,5474,0.0,0.0,6.474999952316284,6.634999978542328,7.067103238900502,5.7915050977280185,-2.4114548115069447,-6.114291043318637,56.97714172106333,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-03,6.599999904632568,6.849999904632568,6.599999904632568,6.849999904632568,4456,0.0,0.0,6.514999961853027,6.627499973773956,7.057853237787882,5.141979197867242,-1.6974728384173359,-6.097509391521586,56.97714172106333,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-04,7.0,7.5,6.900000095367432,6.900000095367432,14845,0.0,0.0,6.5749999523162845,6.6224999785423275,7.0508532404899595,4.942967990998294,-0.7172521914677028,-6.075197530531297,58.11847816580574,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-05,7.099999904632568,7.25,7.099999904632568,7.25,7404,0.0,0.0,6.674999952316284,6.626249980926514,7.043769903977712,8.614232985637486,0.7357098136969755,-5.927506558887158,65.09826809487113,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-07,7.25,7.699999809265137,7.25,7.599999904632568,22653,0.0,0.0,6.7949999332427975,6.6337499737739565,7.043269904454549,11.84694597937396,2.4307512358218335,-5.814343852158637,70.40910207149585,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-10,7.75,7.75,7.75,7.75,26,0.0,0.0,6.934999942779541,6.6537499785423275,7.042353236675263,11.75198361852917,4.226939171808623,-5.5180881315234505,72.3509041993302,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-11,8.0,8.649999618530273,7.949999809265137,8.300000190734863,10613,0.0,0.0,7.134999942779541,6.687499988079071,7.046019903818766,16.327964362974885,6.691588119598801,-5.088261467234661,78.0409562689529,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-12,7.949999809265137,8.300000190734863,7.949999809265137,8.300000190734863,4337,0.0,0.0,7.3199999809265135,6.719999992847443,7.051186573505402,13.387981043195419,8.928571260679934,-4.696891469336258,78.0409562689529,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-13,8.300000190734863,8.300000190734863,8.149999618530273,8.199999809265137,5643,0.0,0.0,7.469999980926514,6.746249985694885,7.058353237311045,9.77242075237703,10.728182275579872,-4.421757329547573,74.79519058862535,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-14,8.149999618530273,8.199999809265137,7.800000190734863,8.0,6228,0.0,0.0,7.6,6.764999985694885,7.066686570644379,5.263157894736848,12.342941848792112,-4.269137762565066,68.64594188845581,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-17,8.0,8.0,8.0,8.0,74,0.0,0.0,7.715000009536743,6.789999985694886,7.077019902070363,3.694102269746729,13.622975343013835,-4.055660720856681,68.64594188845581,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-18,8.300000190734863,11.0,8.0,8.300000190734863,19646,0.0,0.0,7.860000038146973,6.833749985694885,7.086519904931387,5.597966290743455,15.017377788188641,-3.566911864039267,72.56921022108769,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-19,8.5,8.850000381469727,8.449999809265137,8.600000381469727,7232,0.0,0.0,8.030000066757202,6.88125,7.100686573982239,7.098384931181092,16.69391559320185,-3.0903571323128274,75.82664591394581,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-20,8.449999809265137,8.899999618530273,8.0,8.75,14838,0.0,0.0,8.180000066757202,6.9375,7.116103239854177,6.968214285953704,17.90991087217589,-2.5098461030455366,77.27945828048797,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-24,8.300000190734863,8.850000381469727,8.300000190734863,8.699999809265137,14426,0.0,0.0,8.290000057220459,7.0,7.132769906520844,4.945714707053287,18.428572246006553,-1.861407395175672,75.64741049535816,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-25,8.0,8.800000190734863,7.449999809265137,8.600000381469727,19056,0.0,0.0,8.375000095367431,7.058750009536743,7.150103243192037,2.6865705497335157,18.647070431058832,-1.2776491548185114,72.35620413257007,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-26,8.550000190734863,8.649999618530273,8.149999618530273,8.649999618530273,5265,0.0,0.0,8.410000038146972,7.121249997615815,7.168019906679789,2.853740538581283,18.097244738811717,-0.6524801782482538,72.98898380168038,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-27,8.75,8.899999618530273,8.550000190734863,8.800000190734863,8431,0.0,0.0,8.460000038146973,7.195000004768372,7.187186574935913,4.018914315068516,17.581654378599616,0.10871332963175095,74.84903027748288,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-06-28,8.0,8.449999809265137,8.0,8.199999809265137,2346,0.0,0.0,8.460000038146973,7.251250004768371,7.2015199065208435,-3.0732887436107483,16.669540183881896,0.6905500351737975,57.72548285395659,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-01,8.0,8.199999809265137,7.900000095367432,7.949999809265137,14660,0.0,0.0,8.455000019073486,7.275,7.214603237311045,-5.972799629439718,16.21993153365616,0.8371460037692374,52.351347583591654,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-02,7.949999809265137,8.899999618530273,7.949999809265137,8.399999618530273,17828,0.0,0.0,8.494999980926513,7.318749988079071,7.232436565558116,-1.1183091537320828,16.071733489507658,1.1934210793080764,59.63576394389969,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-03,8.399999618530273,8.399999618530273,8.399999618530273,8.399999618530273,3,0.0,0.0,8.504999923706055,7.363749980926514,7.248436562220255,-1.2345715005018842,15.498216883185767,1.5908729795234233,59.63576394389968,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-04,8.449999809265137,8.449999809265137,8.449999809265137,8.449999809265137,268,0.0,0.0,8.489999866485595,7.408749973773956,7.266186559200287,-0.4711432019964979,14.594228399380842,1.9620114817057377,60.415588715898494,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-05,8.449999809265137,8.449999809265137,8.449999809265137,8.449999809265137,200,0.0,0.0,8.45999984741211,7.45499997138977,7.2854365587234495,-0.11820376273449167,13.480883700593582,2.327429678366887,60.415588715898494,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-08,8.550000190734863,8.550000190734863,8.350000381469727,8.350000381469727,203,0.0,0.0,8.424999904632568,7.499999976158142,7.304353229204813,-0.8902020654220052,12.333332418865622,2.67849514959215,57.82435659035303,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-09,8.350000381469727,8.350000381469727,8.350000381469727,8.350000381469727,1,0.0,0.0,8.399999904632569,7.544999980926514,7.323269899686178,-0.5952324253630997,11.332006969747697,3.02774695289925,57.82435659035303,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-10,8.399999618530273,8.850000381469727,8.399999618530273,8.600000381469727,6495,0.0,0.0,8.394999980926514,7.602499985694886,7.344936569531758,2.4419344968311485,10.42420252183916,3.506679924664714,62.48908942026221,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-11,8.399999618530273,8.649999618530273,8.399999618530273,8.5,8595,0.0,0.0,8.364999961853027,7.643749988079071,7.3637699047724405,1.6138677676343705,9.435813244792053,3.802129709745219,59.64723575359745,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-12,8.5,8.5,8.5,8.5,0,0.0,0.0,8.394999980926514,7.688749992847443,7.382103236516317,1.2507447208105653,9.185498146461631,4.153921267509066,59.64723575359745,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-15,8.75,8.899999618530273,8.75,8.899999618530273,3593,0.0,0.0,8.489999961853027,7.746249985694885,7.404436568419139,4.829206814127716,9.601419751901052,4.616332574629975,66.67737608124938,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-16,8.899999618530273,8.899999618530273,8.550000190734863,8.899999618530273,1068,0.0,0.0,8.539999961853027,7.806249976158142,7.42676990032196,4.2154526731301365,9.399519461148508,5.10962478882954,66.67737608124938,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-17,8.899999618530273,8.899999618530273,8.899999618530273,8.899999618530273,0,0.0,0.0,8.589999961853028,7.867499971389771,7.451769896348318,3.608843516343538,9.18334913365916,5.578944074013588,66.67737608124938,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-18,8.0,8.899999618530273,8.0,8.899999618530273,2366,0.0,0.0,8.63499994277954,7.932499957084656,7.47593655983607,3.0689018819545213,8.855972133570189,6.107106361782684,66.67737608124938,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-19,8.899999618530273,8.899999618530273,8.899999618530273,8.899999618530273,9787,0.0,0.0,8.679999923706054,7.998749947547912,7.499103224277496,2.5345587184093774,8.516955532120182,6.6627529762874405,66.67737608124938,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-22,9.199999809265137,9.449999809265137,8.949999809265137,9.350000381469727,3671,0.0,0.0,8.779999923706054,8.07249995470047,7.527353227138519,6.492032604973809,8.764322985144387,7.242209992172581,74.04581105990275,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-23,9.350000381469727,10.5,9.350000381469727,10.0,30458,0.0,0.0,8.944999885559081,8.163749957084656,7.561519893010457,11.794299921055606,9.569743470602523,7.964404942330104,80.6884168225633,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-24,10.300000190734863,10.800000190734863,9.850000381469727,9.850000381469727,6328,0.0,0.0,9.069999885559081,8.252499961853028,7.567936563491822,8.599785068934048,9.906088185215708,9.045575271647767,75.86312607500422,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-25,10.0,10.800000190734863,10.0,10.199999809265137,19561,0.0,0.0,9.239999866485595,8.346249961853028,7.580269893010457,10.389609920467176,10.708400883240957,10.104918157978231,79.01635237535893,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-26,10.199999809265137,10.699999809265137,9.600000381469727,10.5,3764,0.0,0.0,9.439999866485596,8.441249966621399,7.5979365587234495,11.228815132483994,11.83177732934671,11.099242555924116,81.27447258150444,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-29,10.699999809265137,10.699999809265137,10.5,10.699999809265137,7001,0.0,0.0,9.619999885559082,8.541249966621399,7.617436559995015,11.226610567088263,12.629883484892282,12.127615364439448,82.61746028621589,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-30,10.699999809265137,11.899999618530273,10.699999809265137,11.100000381469727,14145,0.0,0.0,9.839999961853028,8.647499978542328,7.639103229840597,12.804882362818834,13.790112590572273,13.20045977075732,84.94331720011843,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-07-31,10.699999809265137,11.699999809265137,10.600000381469727,11.199999809265137,3916,0.0,0.0,10.069999980926514,8.756249976158141,7.658603231112163,11.221448167616122,15.003568974680972,14.332205389449083,85.46685838833275,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-01,11.199999809265137,11.399999618530273,11.199999809265137,11.300000190734863,453,0.0,0.0,10.310000038146972,8.866249978542328,7.682436569531759,9.602329281521756,16.28366065809941,15.409348301104453,85.99142930000977,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-02,11.300000190734863,13.0,11.300000190734863,12.0,8207,0.0,0.0,10.620000076293945,8.984999978542328,7.709769900639852,12.99434947073591,18.19699612305251,16.54044276725615,88.98782275879582,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-05,12.199999809265137,13.0,11.300000190734863,11.300000190734863,7954,0.0,0.0,10.815000057220459,9.077499985694885,7.730103238423665,4.484513462305549,19.140733398663482,17.430514259806742,72.32719628707959,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-06,11.5,12.0,10.199999809265137,11.800000190734863,25620,0.0,0.0,10.995000076293945,9.178749990463256,7.754269909858704,7.321510767212818,19.787553727008326,18.37026692601301,75.810872031262,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-07,12.0,13.0,11.899999618530273,13.0,10180,0.0,0.0,11.310000038146972,9.296249985694885,7.788269909222921,14.942528347947883,21.661961065492598,19.362195892648824,81.74918085683758,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-08,13.0,13.399999618530273,11.100000381469727,13.0,48316,0.0,0.0,11.59000005722046,9.413749980926514,7.822269908587137,12.165659498000815,23.11778070060615,20.34550189315611,81.74918085683758,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-09,12.100000381469727,13.0,11.699999809265137,12.600000381469727,20953,0.0,0.0,11.800000095367432,9.52374999523163,7.852936577796936,6.779663386751726,23.900775443239063,21.276288187003583,74.66324531412884,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-12,12.5,14.0,12.5,12.800000190734863,12286,0.0,0.0,12.010000133514405,9.64375,7.886436581611633,6.577852193489413,24.536618364374892,22.28273061227421,75.79306286738861,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-13,12.600000381469727,12.899999618530273,12.5,12.899999618530273,5763,0.0,0.0,12.190000057220459,9.766249990463256,7.918936578432719,5.824442641321096,24.817612380637343,23.3277965258834,76.36066651212897,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-14,12.800000190734863,13.600000381469727,12.800000190734863,13.199999809265137,15650,0.0,0.0,12.390000057220458,9.888749980926514,7.953936576843262,6.537528234898102,25.293895397480693,24.325230474130034,78.02536541904436,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-15,13.899999618530273,13.899999618530273,13.300000190734863,13.300000190734863,3457,0.0,0.0,12.59000005722046,10.006249976158141,7.993936578432719,5.639397381155797,25.821362520610723,25.172996783018682,78.56717258295743,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-16,13.300000190734863,13.5,11.699999809265137,12.5,10383,0.0,0.0,12.640000057220458,10.099999976158141,8.025269913673402,-1.1075953843883475,25.148515713447427,25.85246458751286,64.80192294663429,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-19,13.899999618530273,14.0,12.899999618530273,12.899999618530273,8715,0.0,0.0,12.8,10.204999971389771,8.059769908587137,0.7812470197677557,25.428711767618246,26.61651743329592,67.8362591049113,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-20,13.199999809265137,13.199999809265137,13.0,13.0,3529,0.0,0.0,12.919999980926514,10.314999961853028,8.095103240013122,0.6191951949813319,25.25448403981878,27.422710446325414,68.56583987521653,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-21,13.800000190734863,13.800000190734863,12.600000381469727,12.600000381469727,3270,0.0,0.0,12.880000019073487,10.413749980926514,8.127103241284688,-2.1739102266235997,23.68263154640812,28.136061173997902,62.462484188642364,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-22,12.899999618530273,12.899999618530273,12.5,12.5,3111,0.0,0.0,12.830000019073486,10.506249976158141,8.16010324160258,-2.5720967933195436,22.11778749019523,28.751434449924893,61.0005711343701,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-23,13.0,13.0,12.399999618530273,12.399999618530273,4250,0.0,0.0,12.809999942779541,10.611249971389771,8.209436571598053,-3.2006270576165576,20.720932758327965,29.256738618350525,59.500851235327616,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-26,12.899999618530273,14.0,12.800000190734863,13.199999809265137,10194,0.0,0.0,12.849999904632568,10.74249997138977,8.264936570326487,2.723734686615752,19.618337806429125,29.976798732593462,66.57966072414781,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-27,13.699999809265137,13.800000190734863,13.100000381469727,13.199999809265137,18605,0.0,0.0,12.879999923706055,10.862499976158142,8.31560323635737,2.484471175889615,18.57307205501568,30.627925207701878,66.57966072414783,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-28,13.199999809265137,13.899999618530273,13.100000381469727,13.199999809265137,6446,0.0,0.0,12.879999923706055,10.982499980926514,8.364769899845124,2.484471175889615,17.27748641998598,31.29470520318626,66.57966072414783,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-29,13.5,13.5,12.899999618530273,13.0,7543,0.0,0.0,12.849999904632568,11.096249985694886,8.407436565558116,1.1673159259196175,15.804888328927246,31.981370292483152,63.13401005296353,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-08-30,13.899999618530273,13.899999618530273,12.199999809265137,12.600000381469727,13549,0.0,0.0,12.859999942779542,11.2,8.454103235403696,-2.021769537065948,14.82142806053163,32.480047713365565,56.80244102223271,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-02,12.5,12.5,11.699999809265137,11.699999809265137,11065,0.0,0.0,12.739999961853027,11.283749985694886,8.494936565558115,-8.1632665282726,12.905727067724113,32.82912589887652,45.69766357995854,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-03,11.699999809265137,13.199999809265137,11.199999809265137,12.300000190734863,20916,0.0,0.0,12.669999980926514,11.382499980926514,8.542769900957744,-2.9202824842040287,11.31122338816116,33.241327027319365,52.381313521164394,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-04,12.300000190734863,12.800000190734863,12.100000381469727,12.100000381469727,4595,0.0,0.0,12.619999980926513,11.469999980926513,8.588269905249279,-4.120440572446105,10.026155204118027,33.55425606635718,50.16486540684113,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-05,12.399999618530273,12.399999618530273,12.399999618530273,12.399999618530273,100,0.0,0.0,12.609999942779542,11.56749997138977,8.636436569690705,-1.6653475432370164,9.012318772147971,33.93834225547997,53.35329896559543,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-06,12.0,12.0,12.0,12.0,1639,0.0,0.0,12.569999980926514,11.65499997138977,8.68093657096227,-4.534606060393172,7.8507079518048,34.25970661248397,48.86422405209411,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-09,12.0,12.399999618530273,12.0,12.100000381469727,4599,0.0,0.0,12.460000038146973,11.734999990463256,8.726269908746083,-2.889242821629915,6.178100113105289,34.47899403961379,49.996934656896606,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-10,12.100000381469727,12.100000381469727,11.800000190734863,11.800000190734863,1423,0.0,0.0,12.320000076293946,11.807500004768372,8.768769911924998,-4.220778265737696,4.340462175046409,34.6540064725713,46.657878942734534,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-11,11.800000190734863,12.899999618530273,11.800000190734863,12.100000381469727,5239,0.0,0.0,12.210000133514404,11.887500023841858,8.814603249231974,-0.9008988602935925,2.712934671089231,34.861430375526304,50.23696261250619,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-12,12.100000381469727,12.100000381469727,11.699999809265137,11.699999809265137,3416,0.0,0.0,12.080000114440917,11.95750002861023,8.857103248437246,-3.145697860726946,1.0244623503038763,35.00463631515214,45.822256408543815,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-13,11.899999618530273,12.199999809265137,11.600000381469727,12.199999809265137,5704,0.0,0.0,12.040000057220459,12.0400000333786,8.903603247801463,1.3289015887398214,1.9802207806753006e-07,35.226151685853665,51.55333536028145,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-16,12.399999618530273,12.399999618530273,11.600000381469727,11.600000381469727,5153,0.0,0.0,12.030000114440918,12.0962500333786,8.943269916375478,-3.574395086289453,-0.5476897282618268,35.25533889153779,45.353353759856894,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-17,12.0,12.800000190734863,11.899999618530273,12.199999809265137,10417,0.0,0.0,12.020000076293945,12.15125002861023,8.987936580181122,1.4975019286912516,-1.0801353935377485,35.195102014898296,51.619348527708446,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-18,11.800000190734863,11.800000190734863,11.699999809265137,11.699999809265137,2689,0.0,0.0,11.980000019073486,12.197500014305115,9.03087984720866,-2.3372304621248605,-1.7831522441200804,35.0643594054152,46.803139255574834,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-19,11.699999809265137,12.399999618530273,11.5,12.100000381469727,10279,0.0,0.0,11.950000095367432,12.24500002861023,9.0774773756663,1.2552325096670394,-2.4091460396368745,34.894305123084145,50.761142022757504,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-20,12.399999618530273,14.300000190734863,12.300000190734863,13.0,15501,0.0,0.0,12.050000095367432,12.30750002861023,9.131735360622406,7.8838165735599555,-2.0922196436661307,34.77723064207775,58.282184540877125,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-23,12.899999618530273,14.100000381469727,12.899999618530273,13.899999618530273,6745,0.0,0.0,12.230000019073486,12.387500023841858,9.18739582300186,13.654943555619898,-1.271443022928239,34.83146108528504,64.17521106761984,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-24,13.899999618530273,13.899999618530273,13.5,13.600000381469727,3350,0.0,0.0,12.410000038146972,12.450000023841858,9.244166660308839,9.589043832915591,-0.3212850250464682,34.67952798057748,61.07804513077304,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-25,13.600000381469727,14.100000381469727,13.300000190734863,13.800000190734863,4827,0.0,0.0,12.580000019073486,12.515000033378602,9.299583327770232,9.69793457719907,0.519376632213532,34.5759222997288,62.38149059796692,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-26,13.300000190734863,13.800000190734863,13.300000190734863,13.600000381469727,8335,0.0,0.0,12.770000076293945,12.572500038146973,9.353749998410542,6.499610808276994,1.5708891433503673,34.41133278399984,60.210030989183636,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-27,13.899999618530273,13.899999618530273,13.600000381469727,13.699999809265137,934,0.0,0.0,12.920000076293945,12.615000033378601,9.408749997615814,6.037149600349936,2.4177569727176413,34.077322030825066,60.942109084623176,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-09-30,13.699999809265137,13.699999809265137,13.600000381469727,13.600000381469727,888,0.0,0.0,13.120000076293945,12.672500038146973,9.461249999205272,3.6585388901260543,3.5312687851639333,33.94107585373434,59.758072622245244,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-01,14.100000381469727,14.100000381469727,12.5,13.399999618530273,12488,0.0,0.0,13.24000005722046,12.712500023841859,9.514999997615813,1.2084558959088347,4.1494594484900125,33.604834755935336,57.35780885368104,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-02,13.199999809265137,13.300000190734863,13.199999809265137,13.199999809265137,1200,0.0,0.0,13.390000057220458,12.717500019073487,9.567083330949147,-1.41897122586542,5.287989283572772,32.929750678901925,54.97961792715338,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-03,13.199999809265137,13.399999618530273,12.600000381469727,13.100000381469727,10061,0.0,0.0,13.49000005722046,12.72000002861023,9.617916667461396,-2.891027976993874,6.053459330804415,32.253173617562794,53.77896029980413,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-04,13.0,14.899999618530273,13.0,13.699999809265137,21755,0.0,0.0,13.560000038146972,12.747500014305114,9.672499998410542,1.032446686757502,6.3737989639543375,31.79116067614246,59.49464097187196,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-07,13.600000381469727,13.699999809265137,13.5,13.5,2608,0.0,0.0,13.520000076293945,12.765000009536744,9.724583331743876,-0.14792955755239395,5.914610780988172,31.26526426965833,56.965887213109,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-08,13.5,13.699999809265137,12.899999618530273,13.199999809265137,6518,0.0,0.0,13.480000019073486,12.772500014305114,9.776249996821086,-2.077152888814274,5.539244501671377,30.64825488769528,53.30589181345733,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-09,13.300000190734863,13.300000190734863,12.899999618530273,12.899999618530273,644,0.0,0.0,13.389999961853027,12.765000009536744,9.82916665871938,-3.659449923216751,4.8962001711660434,29.86858858693791,49.85627998890497,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-10,12.100000381469727,13.0,12.100000381469727,12.800000190734863,2242,0.0,0.0,13.309999942779541,12.752500009536742,9.879999995231628,-3.831703638145726,4.371691298379781,29.073886798496606,48.72439541586143,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-11,12.800000190734863,13.699999809265137,12.800000190734863,13.100000381469727,26852,0.0,0.0,13.25,12.767500019073486,9.934999998410543,-1.132072592681309,3.7791265338218354,28.510317273438375,52.22837061627402,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-14,14.399999618530273,15.0,13.5,14.5,16805,0.0,0.0,13.339999961853028,12.80750002861023,10.004166666666666,8.695652484738382,4.157719555364162,28.021657928632038,64.44061622557213,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-15,14.399999618530273,14.399999618530273,14.0,14.0,5658,0.0,0.0,13.4,12.83250002861023,10.06875,4.477611940298504,4.422364855831065,27.44878985584338,58.67186102306332,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-16,13.600000381469727,13.899999618530273,13.5,13.5,3253,0.0,0.0,13.430000019073486,12.855000019073486,10.129999999205271,0.5212210039247905,4.4729677102049665,26.900296348292198,53.51286371488129,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-17,13.800000190734863,14.100000381469727,13.800000190734863,14.100000381469727,1801,0.0,0.0,13.530000019073487,12.89500002861023,10.198750003178914,4.212862982946782,4.924389213294903,26.437063606725385,58.256295214924485,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-18,13.5,14.199999809265137,13.5,14.199999809265137,1292,0.0,0.0,13.580000019073486,12.9400000333786,10.267500003178915,4.565536003835375,4.945904049799163,26.02873172020701,59.007052674640626,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-21,14.199999809265137,14.199999809265137,14.100000381469727,14.100000381469727,4280,0.0,0.0,13.640000057220458,12.962500047683715,10.326666673024496,3.372436380641824,5.226615290603656,25.524532340572108,57.88589650054571,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-22,14.100000381469727,14.399999618530273,14.100000381469727,14.399999618530273,2161,0.0,0.0,13.760000038146973,12.992500042915344,10.391250002384187,4.651159728263251,5.907254128893678,25.03308110125656,60.32159598408508,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-23,14.399999618530273,15.199999809265137,14.100000381469727,14.100000381469727,13203,0.0,0.0,13.880000114440918,13.015000057220458,10.45375000635783,1.5850163199920848,6.646177897944574,24.50077770469842,56.78477762182777,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-24,14.399999618530273,14.899999618530273,14.0,14.899999618530273,4741,0.0,0.0,14.09000005722046,13.062500047683717,10.522500002384186,5.74875484755394,7.866028752428157,24.138750722014898,63.01274268530906,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-25,14.800000190734863,14.800000190734863,13.699999809265137,14.0,3339,0.0,0.0,14.180000019073486,13.097500038146972,10.584166669845581,-1.2693936447910297,8.264935886800465,23.746162042798396,53.64608066528741,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-28,13.699999809265137,14.300000190734863,13.699999809265137,14.100000381469727,3292,0.0,0.0,14.140000057220458,13.157500052452088,10.647083338101705,-0.2828831371206838,7.467224023193278,23.57844523829914,54.45616471565075,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-29,14.100000381469727,14.899999618530273,14.100000381469727,14.800000190734863,18648,0.0,0.0,14.220000076293946,13.220000052452088,10.715833338101705,4.078763089515245,7.564296670758145,23.368847156725124,59.757761560749756,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-30,14.800000190734863,14.899999618530273,14.5,14.5,7083,0.0,0.0,14.320000076293946,13.280000042915344,10.78416666984558,1.2569827007475742,7.831325527242184,23.143497772976286,56.710905264071876,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-10-31,14.800000190734863,14.800000190734863,14.399999618530273,14.399999618530273,1213,0.0,0.0,14.35,13.330000042915344,10.847083334128062,0.34842939742351076,7.651912631663997,22.890178237824617,55.691581819797356,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-01,14.5,14.5,14.5,14.5,36,0.0,0.0,14.380000019073487,13.392500042915344,10.912083335717519,0.8344922167409357,7.373529759147036,22.730917927275225,56.53295798201515,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-04,14.399999618530273,14.699999809265137,14.300000190734863,14.699999809265137,430,0.0,0.0,14.439999961853028,13.45750002861023,10.97958333492279,1.800552964674276,7.300761145487892,22.568403718981976,58.24087949551158,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-05,14.800000190734863,15.0,14.5,14.5,2906,0.0,0.0,14.45,13.525000023841859,11.046250001589458,0.3460207612456797,6.839186502976351,22.439742192108003,55.87647641207782,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-06,14.399999618530273,14.399999618530273,14.399999618530273,14.399999618530273,14,0.0,0.0,14.479999923706055,13.582500004768372,11.1125,-0.5524882983238724,6.607766748555864,22.227221640210313,54.681146027673535,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-07,14.399999618530273,14.399999618530273,14.100000381469727,14.100000381469727,3000,0.0,0.0,14.4,13.642500019073486,11.177500001589458,-2.083330684238012,5.552501226809301,22.05323209244913,51.14625550288955,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-08,14.399999618530273,14.600000381469727,14.300000190734863,14.5,167,0.0,0.0,14.45,13.700000023841858,11.246250001589457,0.3460207612456797,5.474452371189274,21.818384100527787,55.29589068299081,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-11,14.5,14.600000381469727,14.5,14.600000381469727,2649,0.0,0.0,14.5,13.775000023841859,11.314583337306976,0.6896578032394935,5.2631577125466915,21.745535060246375,56.29535303475722,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-12,14.5,14.5,14.199999809265137,14.199999809265137,1643,0.0,0.0,14.439999961853028,13.825000023841858,11.380000003178914,-1.6620509225894258,4.448462473421874,21.485061686994307,51.34993996186695,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-13,14.300000190734863,14.5,14.300000190734863,14.5,798,0.0,0.0,14.439999961853028,13.89500002861023,11.44833333492279,0.4155127306473534,3.9222737108357393,21.371378890794162,54.573147526995434,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-14,14.399999618530273,14.5,14.399999618530273,14.399999618530273,1097,0.0,0.0,14.439999961853028,13.952500009536744,11.514583333333333,-0.2770106885625031,3.4939971473432765,21.172426353856295,53.305376799013914,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-15,14.5,14.5,14.399999618530273,14.399999618530273,2037,0.0,0.0,14.429999923706054,13.9875,11.578749998410542,-0.2079023238697005,3.1635383285508745,20.803195525597467,53.305376799013914,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-18,14.399999618530273,16.200000762939453,14.300000190734863,15.699999809265137,11012,0.0,0.0,14.529999923706054,14.032500004768371,11.653749998410543,8.052304829335883,3.5453405933983806,20.41188464384654,65.41768484986257,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-19,15.899999618530273,17.600000381469727,15.800000190734863,16.299999237060547,4065,0.0,0.0,14.70999984741211,14.099999976158141,11.732499992847442,10.808969450316894,4.326240228974644,20.178989855137548,69.3671601037617,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-20,16.200000762939453,18.399999618530273,16.200000762939453,16.899999618530273,10290,0.0,0.0,14.95999984741211,14.177499961853027,11.816249990463257,12.967913040813023,5.519307971536113,19.98307393035442,72.72207864233039,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-21,17.0,17.600000381469727,17.0,17.100000381469727,3958,0.0,0.0,15.259999847412109,14.264999961853027,11.901249992847443,12.057670723828066,6.975113131579927,19.86135885244137,73.75394524914043,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-22,16.399999618530273,17.399999618530273,16.399999618530273,16.700000762939453,17454,0.0,0.0,15.479999923706055,14.339999985694885,11.97999999920527,7.881142411151373,7.949790370630384,19.699499053807777,68.19754367272397,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-25,17.899999618530273,17.899999618530273,16.700000762939453,16.799999237060547,2544,0.0,0.0,15.699999809265137,14.419999957084656,12.056666660308839,7.00636586725473,8.876559334187844,19.6018797181814,68.8297618367846,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-26,17.200000762939453,17.200000762939453,16.799999237060547,16.899999618530273,1032,0.0,0.0,15.96999979019165,14.507499957084656,12.132916657129924,5.823417912064121,10.080991469469492,19.571413593773478,69.48310244289522,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-27,16.600000381469727,17.100000381469727,15.5,16.600000381469727,10927,0.0,0.0,16.179999828338623,14.59249997138977,12.202083325386047,2.5958007267434535,10.878875176024147,19.59023375156386,65.07628119767182,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-28,16.600000381469727,16.799999237060547,15.800000190734863,16.200000762939453,7776,0.0,0.0,16.35999994277954,14.669999980926514,12.267916663487751,-0.9779901002426591,11.520108821065534,19.58020569692926,59.64451744714056,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-11-29,15.800000190734863,15.899999618530273,13.699999809265137,14.300000190734863,12508,0.0,0.0,16.35,14.684999990463258,12.31875,-12.53822513312011,11.33810017445032,19.20852351466876,41.798028680344096,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-02,15.0,15.5,14.5,14.699999809265137,1527,0.0,0.0,16.25,14.714999985694885,12.374583331743876,-9.538462712214542,10.43153255723655,18.913094616666882,45.49550261875187,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-03,14.600000381469727,14.800000190734863,14.5,14.800000190734863,7851,0.0,0.0,16.10000009536743,14.754999995231628,12.43125,-8.074533521317344,9.11555473107737,18.692810419158395,46.41206330560085,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-04,14.5,14.5,13.199999809265137,14.100000381469727,24841,0.0,0.0,15.820000171661377,14.785000014305115,12.47958333492279,-10.872312082984132,7.0003392381119705,18.473506827193994,41.19043223333066,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-05,14.5,14.5,13.399999618530273,14.0,20540,0.0,0.0,15.510000133514405,14.815000009536742,12.524583331743877,-9.735655193526128,4.691192193926934,18.287368267076367,40.4896108741841,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-06,14.100000381469727,14.899999618530273,13.600000381469727,14.0,9506,0.0,0.0,15.24000005722046,14.8375,12.568333331743876,-8.13648328454545,2.7127215313931545,18.0546346787675,40.489610874184095,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-09,13.800000190734863,15.600000381469727,13.699999809265137,14.899999618530273,9584,0.0,0.0,15.050000095367432,14.847499990463257,12.619999996821086,-0.996680902901326,1.3638666781225341,17.65055462918595,49.46429802383285,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-10,15.0,15.0,14.399999618530273,14.899999618530273,5968,0.0,0.0,14.850000095367431,14.869999980926513,12.672499990463256,0.3366971235134216,-0.1344982218206852,17.34069830039057,49.46429802383286,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-11,15.100000381469727,15.600000381469727,15.0,15.0,3116,0.0,0.0,14.690000057220459,14.907499980926513,12.725416660308838,2.110278703689788,-1.4589966391704545,17.14744105333457,50.42767119608066,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-12,15.100000381469727,15.100000381469727,14.600000381469727,14.600000381469727,884,0.0,0.0,14.530000019073487,14.919999980926514,12.77374999523163,0.4817643654807313,-2.6139407664316128,16.802035318493537,46.60089465012354,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-13,14.899999618530273,15.100000381469727,14.199999809265137,14.600000381469727,8115,0.0,0.0,14.560000038146972,14.92999999523163,12.827083333333333,0.27472763199144223,-2.478231461505881,16.394347859528708,46.60089465012354,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-16,14.300000190734863,14.5,13.300000190734863,13.300000190734863,2481,0.0,0.0,14.420000076293945,14.909999990463257,12.871666669845581,-7.766989456541881,-3.2863844029693214,15.835814995061007,36.23613444201743,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-17,13.5,14.0,13.5,13.5,13030,0.0,0.0,14.290000057220459,14.8875,12.914166673024495,-5.528341875837061,-4.0134337046484685,15.28037679037753,38.50231556233736,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-18,13.600000381469727,13.600000381469727,13.300000190734863,13.300000190734863,828,0.0,0.0,14.210000038146973,14.86749999523163,12.9550000111262,-6.40393979570162,-4.422397560420601,14.762639772002375,37.08299823893619,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-19,13.100000381469727,13.100000381469727,12.800000190734863,12.899999618530273,858,0.0,0.0,14.1,14.817499995231628,12.992083342870076,-8.510641003331392,-4.8422473120467355,14.050222771726,34.35526630416115,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-20,12.899999618530273,12.899999618530273,12.800000190734863,12.899999618530273,2518,0.0,0.0,13.989999961853027,14.789999985694886,13.029166674613952,-7.791281960649689,-5.409060342228744,13.514550508527485,34.35526630416115,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-23,12.600000381469727,13.399999618530273,11.399999618530273,11.899999618530273,32385,0.0,0.0,13.689999961853028,14.734999966621398,13.058750001589457,-13.07523994383172,-7.091957971737814,12.836220655330063,28.316191116151288,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-27,11.300000190734863,12.0,11.100000381469727,12.0,25393,0.0,0.0,13.4,14.664999961853027,13.08916666507721,-10.447761194029853,-8.625979987341132,12.039217905141726,29.647993975384466,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2024-12-30,11.600000381469727,12.0,10.899999618530273,12.0,18568,0.0,0.0,13.1,14.602499961853027,13.11749999523163,-8.396946564885493,-10.289333783791111,11.320754466637803,29.647993975384466,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-02,13.100000381469727,13.199999809265137,12.0,13.0,11898,0.0,0.0,12.939999961853028,14.56749997138977,13.154999995231629,0.46367881239452646,-11.172129828269192,10.737362042342369,42.11949888855929,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-03,12.899999618530273,13.699999809265137,12.399999618530273,13.5,9795,0.0,0.0,12.829999923706055,14.54249997138977,13.196666661898295,5.222136245347771,-11.775829816419508,10.198282217563277,47.16303280661262,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-07,13.899999618530273,13.899999618530273,12.600000381469727,13.600000381469727,6401,0.0,0.0,12.859999942779542,14.514999985694885,13.235833334922791,5.754280264252025,-11.401998240071736,9.66442095789321,48.13641089789516,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-08,13.600000381469727,13.699999809265137,13.100000381469727,13.5,4461,0.0,0.0,12.859999942779542,14.489999985694885,13.274166671435038,4.976672317792636,-11.249137643371602,9.15939466751027,47.199991737239856,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-09,13.399999618530273,13.399999618530273,13.0,13.399999618530273,7454,0.0,0.0,12.869999885559082,14.464999985694885,13.311666671435038,4.118102079906645,-11.026616672749206,8.664078982196402,46.23144903111199,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-10,12.899999618530273,13.399999618530273,12.899999618530273,13.100000381469727,4905,0.0,0.0,12.889999961853027,14.439999985694886,13.346666677792866,1.6291731593342111,-10.734072197904295,8.191807994434937,43.357095331666024,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-13,13.199999809265137,13.699999809265137,12.199999809265137,13.699999809265137,6220,0.0,0.0,12.969999980926513,14.419999980926514,13.386666679382325,5.628371853601777,-10.055478515380939,7.71912326117519,50.04645280679133,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-14,13.199999809265137,13.699999809265137,13.0,13.100000381469727,22894,0.0,0.0,13.09000005722046,14.382499980926514,13.417916679382325,0.07639667078344306,-8.98661516023025,7.188770988765694,44.39964426653192,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-15,13.199999809265137,13.600000381469727,12.899999618530273,13.199999809265137,4588,0.0,0.0,13.210000038146973,14.357499980926514,13.444583344459534,-0.07570195952277012,-7.992338111119338,6.790218879063957,45.503294283507906,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-16,13.100000381469727,13.699999809265137,13.100000381469727,13.699999809265137,3551,0.0,0.0,13.380000019073487,14.337499976158142,13.476666673024495,2.3916277259752112,-6.678290906203202,6.3875832505135,50.76563887801683,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-17,13.899999618530273,13.899999618530273,13.399999618530273,13.899999618530273,697,0.0,0.0,13.469999980926513,14.324999976158143,13.50750000476837,3.1922764529520338,-5.968586364081338,6.052193012039096,52.73181414330701,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-20,14.0,14.0,12.800000190734863,13.899999618530273,4311,0.0,0.0,13.50999994277954,14.312499976158142,13.53583333492279,2.886748167302322,-5.606987142116411,5.737856118777202,52.73181414330701,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-21,13.699999809265137,13.699999809265137,13.199999809265137,13.5,13502,0.0,0.0,13.499999904632569,14.257499980926514,13.559166669845581,7.064254219189141e-07,-5.312993703716071,5.15026718149255,48.26134873525395,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-22,13.5,13.5,13.300000190734863,13.300000190734863,79,0.0,0.0,13.479999923706055,14.182500004768372,13.577500001589458,-1.335309599331989,-4.9532880721038275,4.455901330201354,46.15442851272091,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-23,13.100000381469727,13.5,12.800000190734863,13.399999618530273,2240,0.0,0.0,13.479999923706055,14.095000004768371,13.595833333333333,-0.5934740773632522,-4.363249952850374,3.671468009329118,47.39111704650925,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-24,13.399999618530273,14.699999809265137,13.399999618530273,14.0,16726,0.0,0.0,13.569999885559081,14.017499995231628,13.618333331743877,3.168755475808928,-3.1924388073820134,2.9310977618480454,54.18961512192186,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-27,14.0,14.699999809265137,14.0,14.399999618530273,20228,0.0,0.0,13.639999866485596,13.9599999666214,13.638333328564961,5.571845744016821,-2.2922643331012154,2.3585480007496225,58.078978242056266,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-28,14.300000190734863,14.300000190734863,14.300000190734863,14.300000190734863,1876,0.0,0.0,13.759999847412109,13.897499990463256,13.663333328564962,3.9244211432481517,-0.9893876103292136,1.7138326078069022,56.781079482989796,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-29,14.5,14.600000381469727,14.199999809265137,14.199999809265137,6882,0.0,0.0,13.859999847412109,13.829999995231628,13.683333325386048,2.4531022048785354,0.2169186709387162,1.0718636048533279,55.44667892959542,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-30,14.0,14.0,13.800000190734863,13.899999618530273,230,0.0,0.0,13.879999828338622,13.762499976158143,13.690833322207133,0.14409070921469164,0.8537682280402088,0.5234645128194124,51.53394333051963,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-01-31,14.0,14.0,14.0,14.0,800,0.0,0.0,13.889999866485596,13.707499957084655,13.699166655540466,0.7919376139075239,1.3313872695408335,0.06083071878550213,52.73135349193598,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-03,13.800000190734863,14.199999809265137,13.600000381469727,14.100000381469727,3473,0.0,0.0,13.90999994277954,13.702499961853027,13.711666655540466,1.3659269552248423,1.514322068996035,-0.06685324197065882,53.956418224229196,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-04,14.0,14.399999618530273,14.0,14.300000190734863,780,0.0,0.0,13.989999961853027,13.69249997138977,13.724166655540467,2.215870119564861,2.1727222281166867,-0.23073666289175104,56.39073581611997,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-05,14.300000190734863,15.0,13.600000381469727,15.0,6185,0.0,0.0,14.15999994277954,13.697499966621399,13.74166665871938,5.932203817901791,3.3765283977746305,-0.32140709853383465,63.637093259266756,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-06,14.5,14.800000190734863,14.399999618530273,14.800000190734863,2097,0.0,0.0,14.3,13.714999961853028,13.754999995231628,3.4965048303137243,4.265403133606233,-0.2908035870044854,60.5417263344811,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-07,14.600000381469727,15.0,14.600000381469727,15.0,1191,0.0,0.0,14.4,13.739999961853027,13.769166660308837,4.166666666666664,4.803493740752264,-0.211826170569108,62.50576908452273,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-10,15.100000381469727,15.199999809265137,14.399999618530273,14.600000381469727,12739,0.0,0.0,14.420000076293945,13.75499997138977,13.786666663487752,1.248268406542497,4.834606370682422,-0.22969070675979458,56.453497747943196,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-11,14.699999809265137,16.399999618530273,14.600000381469727,16.399999618530273,13083,0.0,0.0,14.630000019073487,13.79249997138977,13.815833330154419,12.098425134307554,6.072141014471419,-0.1688885368479496,70.36122061953819,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-12,15.800000190734863,16.0,15.5,15.5,10321,0.0,0.0,14.760000038146973,13.807499980926513,13.836666663487753,5.01354986409559,6.898425193092379,-0.21079269502245584,60.036611652746835,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-13,15.199999809265137,15.300000190734863,14.899999618530273,15.300000190734863,5251,0.0,0.0,14.900000095367432,13.814999985694886,13.859166661898294,2.6845643812565876,7.853782922881204,-0.31868204835743713,57.99985522178167,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-14,15.300000190734863,15.899999618530273,15.300000190734863,15.300000190734863,6888,0.0,0.0,15.030000114440918,13.832499980926514,13.882499996821085,1.7964076795616735,8.657148998124885,-0.36016579078711375,57.999855221781665,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-17,15.899999618530273,17.899999618530273,15.899999618530273,16.600000381469727,24926,0.0,0.0,15.280000114440918,13.882499980926514,13.917500003178914,8.638745138367467,10.066631625675933,-0.2514821070192548,66.5535876952033,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-18,16.799999237060547,17.600000381469727,16.299999237060547,17.100000381469727,40095,0.0,0.0,15.560000133514404,13.977499985694886,13.950000007947287,9.897173745123204,11.321768194878267,0.19713245685973022,69.15550677917875,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-19,17.5,17.5,17.100000381469727,17.5,11250,0.0,0.0,15.810000133514404,14.077499985694885,13.985833342870077,10.689436130383678,12.306873731699739,0.6554249616562163,71.09292196027047,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-20,17.5,18.700000762939453,17.5,18.600000381469727,35912,0.0,0.0,16.190000152587892,14.209999990463256,14.030833347638447,14.885733206720248,13.933850552100433,1.276949404113368,75.62685034896509,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-21,18.600000381469727,18.700000762939453,17.0,17.200000762939453,11030,0.0,0.0,16.410000228881835,14.317500019073487,14.065833353996277,4.814140908220137,14.614983111721747,1.7892055077256255,62.24554451279874,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-24,17.200000762939453,18.0,16.299999237060547,17.799999237060547,2748,0.0,0.0,16.73000011444092,14.440000009536742,14.109166677792867,6.395691065752181,15.858726477782348,2.344811279780191,65.09594133453271,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-25,17.299999237060547,20.799999237060547,16.700000762939453,20.799999237060547,41377,0.0,0.0,17.170000076293945,14.6625,14.185000006357829,21.141520935567275,17.101449795696137,3.366231888813196,75.18428220362688,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-26,20.799999237060547,21.200000762939453,17.399999618530273,18.0,55707,0.0,0.0,17.420000076293945,14.8125,14.232500004768372,3.329505862031248,17.60337604249077,4.0751800108013905,58.259233529489066,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-27,18.0,18.0,16.299999237060547,17.0,21187,0.0,0.0,17.590000057220458,14.9375,14.27333333492279,-3.3541788249072257,17.75732255879804,4.653199427860218,53.61694918596817,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-02-28,16.399999618530273,17.0,16.399999618530273,16.799999237060547,3017,0.0,0.0,17.739999961853027,15.032499980926513,14.309999998410543,-5.298763961746324,18.010976114164876,5.048916719749967,52.7122691247743,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-03,17.0,18.600000381469727,16.700000762939453,18.299999237060547,12087,0.0,0.0,17.90999984741211,15.152499961853028,14.362499992052713,2.17755104953164,18.198316399941845,5.500434953785552,58.383792313594206,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-04,18.0,18.0,16.5,18.0,13645,0.0,0.0,17.999999809265137,15.262499952316285,14.411666655540467,1.059638136621148e-06,17.93611705488262,5.90378140927039,56.91357781935425,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-05,18.600000381469727,18.899999618530273,18.100000381469727,18.700000762939453,5348,0.0,0.0,18.119999885559082,15.392499971389771,14.469166660308838,3.2008878644784575,17.719668145128786,6.3813855542474265,59.47773785480815,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-06,18.600000381469727,18.600000381469727,16.799999237060547,17.5,6542,0.0,0.0,18.00999984741211,15.494999980926513,14.514166657129923,-2.831759310011286,16.231041430018863,6.757765340352948,53.589906206786935,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-07,17.100000381469727,17.299999237060547,17.0,17.299999237060547,350,0.0,0.0,18.019999694824218,15.599999952316285,14.560833319028218,-3.995563096321654,15.512818909647574,7.13672501099285,52.65434973262861,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-10,17.100000381469727,17.700000762939453,17.100000381469727,17.700000762939453,918,0.0,0.0,18.00999984741211,15.699999976158143,14.606666660308838,-1.7212608944980197,14.713374998483502,7.485166474157001,54.37008908142379,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-11,17.399999618530273,17.399999618530273,16.600000381469727,16.600000381469727,5035,0.0,0.0,17.589999961853028,15.787499976158141,14.648333326975505,-5.628195466346149,11.417260417526357,7.776766296578014,49.100540971137804,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-12,15.300000190734863,15.699999809265137,14.199999809265137,14.899999618530273,13704,0.0,0.0,17.279999923706054,15.829999971389771,14.670833325386047,-13.773149975022339,9.15982283598818,7.901164305356335,42.28039960696691,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-13,14.899999618530273,15.300000190734863,14.800000190734863,14.800000190734863,5016,0.0,0.0,17.05999994277954,15.857499980926514,14.696666661898295,-13.247360841880882,7.583162309944193,7.898616371545847,41.91161349138191,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-14,14.399999618530273,15.0,13.600000381469727,15.0,8985,0.0,0.0,16.880000019073485,15.884999990463257,14.720833325386048,-11.137440858703714,6.263771036874963,7.908293228682958,42.982783102734615,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-17,14.899999618530273,15.899999618530273,13.899999618530273,15.5,15028,0.0,0.0,16.60000009536743,15.925,14.74166665871938,-6.6265065605295295,4.238619123186375,8.027134032234438,45.67963274390952,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-18,15.699999809265137,17.399999618530273,15.100000381469727,16.5,20148,0.0,0.0,16.450000095367432,16.0,14.763333328564961,0.30395078627779687,2.812500596046452,8.376608750289908,50.701855497644864,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-19,16.399999618530273,16.399999618530273,16.100000381469727,16.100000381469727,2469,0.0,0.0,16.19000005722046,16.07000000476837,14.784166661898295,-0.5558966981633464,0.7467333691131369,8.697367746698372,48.75989541021328,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-20,16.700000762939453,18.200000762939453,16.299999237060547,16.899999618530273,10795,0.0,0.0,16.130000019073485,16.157500004768373,14.809999990463258,4.773711088321608,-0.17019950912438403,9.098582141612585,52.66484082485253,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-21,17.5,18.299999237060547,15.899999618530273,16.0,10878,0.0,0.0,16.000000095367433,16.20750000476837,14.829999987284342,-5.960464530829767e-07,-1.2802709198820859,9.288604306575422,48.21331038427338,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-24,15.800000190734863,15.800000190734863,15.199999809265137,15.399999618530273,2779,0.0,0.0,15.769999980926514,16.232500004768372,14.844166652361553,-2.34622931416454,-2.8492223853750014,9.352720061155809,45.45487434865413,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-25,15.199999809265137,15.300000190734863,15.199999809265137,15.300000190734863,418,0.0,0.0,15.639999961853027,16.25750000476837,14.858333317438762,-2.1739115853417212,-3.798247225798735,9.416713553514452,44.99284444192756,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-26,15.399999618530273,15.399999618530273,15.300000190734863,15.399999618530273,66,0.0,0.0,15.689999961853028,16.2875,14.874999984105427,-1.8483132187879527,-3.6684576401963076,9.495798436328677,45.58845904237951,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-27,15.300000190734863,15.300000190734863,14.899999618530273,15.100000381469727,1106,0.0,0.0,15.719999980926513,16.317500019073485,14.890833322207133,-3.9440178130346575,-3.6617131144388275,9.58083853331917,44.04755610418583,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-28,14.600000381469727,15.0,14.600000381469727,14.899999618530273,3990,0.0,0.0,15.709999942779541,16.340000009536745,14.905833315849303,-5.155953705916794,-3.8555695617472914,9.62151302310954,43.003977463380615,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-03-31,14.800000190734863,14.800000190734863,14.399999618530273,14.399999618530273,2321,0.0,0.0,15.599999904632568,16.347499990463255,14.911666647593181,-7.6923095733221345,-4.572565140032181,9.628925973219935,40.425396970148064,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-01,14.800000190734863,15.699999809265137,14.800000190734863,15.699999809265137,1924,0.0,0.0,15.519999885559082,16.382499980926514,14.929999979337056,1.159793331400338,-5.264764818383068,9.728734116541867,48.98963270639532,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-02,16.799999237060547,16.899999618530273,14.800000190734863,15.300000190734863,8729,0.0,0.0,15.439999866485596,16.389999985694885,14.947499982515971,-0.9067336590761217,-5.796217938001492,9.650443250484697,46.76210872800867,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-03,14.5,15.199999809265137,14.5,15.0,1437,0.0,0.0,15.249999904632569,16.394999980926514,14.964999985694885,-1.6393436471866796,-6.983837009002783,9.555629780144157,45.10559419748846,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-04,15.300000190734863,15.399999618530273,15.0,15.100000381469727,2530,0.0,0.0,15.15999994277954,16.397499990463256,14.984166653951009,-0.39577547187518897,-7.546882441856638,9.432178439763822,45.79489088997754,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-07,17.25,17.25,14.300000190734863,14.800000190734863,2339,0.0,0.0,15.1,16.402499985694885,14.998333319028218,-1.986753703742625,-7.94086259308541,9.362151359079453,44.009516657546065,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-08,15.050000190734863,15.050000190734863,14.949999809265137,15.0,478,0.0,0.0,15.069999980926514,16.36749999523163,15.002499985694886,-0.4644988786669576,-7.927295033958257,9.098483658312226,45.534026519605064,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-09,14.550000190734863,15.800000190734863,14.550000190734863,15.0,2804,0.0,0.0,15.030000019073487,16.35499999523163,15.010833319028219,-0.19960092505266921,-8.10149786942496,8.954643940383388,45.534026519605064,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-10,19.950000762939453,19.950000762939453,14.949999809265137,15.25,8121,0.0,0.0,15.044999980926514,16.353749990463257,15.025416652361551,1.3625790583807065,-8.002751725444895,8.84057573134207,47.60230034862667,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-11,15.300000190734863,16.5,14.949999809265137,16.450000762939453,13044,0.0,0.0,15.200000095367432,16.38250000476837,15.0449999888738,8.223688550850659,-7.218067505305993,8.889996788858028,56.20001330763415,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-14,16.0,16.5,12.399999618530273,14.25,18337,0.0,0.0,15.185000133514404,16.32374999523163,15.045416657129923,-6.157392988431986,-6.976031010336897,8.496496755348499,42.448295083478065,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-15,14.25,16.5,13.899999618530273,15.0,9064,0.0,0.0,15.115000152587891,16.271249985694887,15.052916653951009,-0.7608346108299668,-7.106091014049505,8.093669550904584,47.19225774286179,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-16,14.949999809265137,15.600000381469727,14.699999809265137,15.5,13778,0.0,0.0,15.135000133514405,16.221249985694886,15.06208332379659,2.4116277718250734,-6.696462067586763,7.695925171698708,50.14281628163551,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-17,14.949999809265137,16.149999618530273,14.949999809265137,16.049999237060547,6964,0.0,0.0,15.24000005722046,16.157499957084656,15.078333314259847,5.31495522833888,-5.6784768825693,7.157068492472058,53.23793346888895,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-22,15.949999809265137,15.949999809265137,14.5,15.699999809265137,7518,0.0,0.0,15.3,16.1199999332428,15.08499998251597,2.614377838334222,-5.086848242175158,6.861119999512284,51.065402173000436,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-23,15.100000381469727,15.550000190734863,15.0,15.350000381469727,3579,0.0,0.0,15.355000019073486,16.058749961853028,15.096249985694886,-0.03256032300585722,-4.382345727103753,6.375755416545176,48.91570230985421,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-24,14.449999809265137,14.800000190734863,14.449999809265137,14.800000190734863,441,0.0,0.0,15.335000038146973,15.908749985694886,15.102083317438762,-3.488750218984394,-3.606505527233931,5.341426419788357,45.662640726046725,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-25,15.199999809265137,15.949999809265137,15.149999618530273,15.199999809265137,9071,0.0,0.0,15.355000019073486,15.838749980926513,15.10541664759318,-1.0094445432485402,-3.0542180565737373,4.854770645801273,48.35276585247512,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-28,15.649999618530273,15.699999809265137,15.600000381469727,15.600000381469727,3022,0.0,0.0,15.390000057220458,15.803749990463256,15.114583317438761,1.36452451896349,-2.618049092730994,4.559614106128581,50.967020880440565,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-29,15.5,15.75,15.5,15.699999809265137,7390,0.0,0.0,15.314999961853028,15.776250004768372,15.125416652361553,2.513874295599582,-2.92369886871678,4.302911895687867,51.62624377310899,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-04-30,15.5,15.5,15.399999618530273,15.399999618530273,1086,0.0,0.0,15.429999923706054,15.703750014305115,15.132916649182638,-0.1944284207655088,-1.7432147757681544,3.7721305043552764,49.47714047399971,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-02,15.600000381469727,15.600000381469727,15.350000381469727,15.350000381469727,1310,0.0,0.0,15.464999961853028,15.637500023841858,15.138333320617676,-0.7436119021465691,-1.1031179007247047,3.2973689550377445,49.11020890776294,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-05,15.199999809265137,15.199999809265137,15.050000190734863,15.199999809265137,1370,0.0,0.0,15.434999942779541,15.55,15.144166652361552,-1.5225146380666936,-0.7395502072055286,2.679799799846789,47.961041474410294,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-06,15.0,15.0,14.899999618530273,14.899999618530273,412,0.0,0.0,15.319999980926514,15.484999990463256,15.148333319028218,-2.741516729237231,-1.0655473660856352,2.222466751587401,45.659816954357254,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-07,14.850000381469727,14.899999618530273,14.649999618530273,14.699999809265137,1647,0.0,0.0,15.219999980926513,15.420000004768372,15.153333314259847,-3.4165582937781407,-1.2970170154345833,1.7597889848933936,44.139309151530824,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-08,15.0,15.75,15.0,15.5,1934,0.0,0.0,15.234999942779542,15.364999985694885,15.161666647593181,1.7394162009567455,-0.8460790305003303,1.3411014951577345,51.14722555659911,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-09,15.050000190734863,15.050000190734863,15.0,15.050000190734863,431,0.0,0.0,15.25999994277954,15.326249980926514,15.165416646003724,-1.3761451692799056,-0.4322651544208254,1.0605269784340001,47.534782238502956,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-12,15.050000190734863,15.050000190734863,15.050000190734863,15.050000190734863,0,0.0,0.0,15.244999980926513,15.329999995231628,15.172499982515971,-1.2791065295875386,-0.5544684561745173,1.0380623687404966,47.53478223850296,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-13,14.649999618530273,15.0,14.449999809265137,14.600000381469727,1045,0.0,0.0,15.144999980926514,15.325,15.173333319028218,-3.5985447351809507,-1.1745515110831035,0.9995607279092869,43.93589832641266,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-14,14.5,15.149999618530273,14.399999618530273,15.050000190734863,5237,0.0,0.0,15.080000019073486,15.326250004768372,15.178749990463256,-0.19893785345277393,-1.606720402044022,0.971753368345811,48.162443673564056,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-15,15.050000190734863,16.899999618530273,14.649999618530273,15.850000381469727,5399,0.0,0.0,15.125000095367431,15.335000014305114,15.190833330154419,4.793390291113799,-1.3694158378988366,0.9490373636350729,54.700603405143525,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-16,15.949999809265137,15.949999809265137,15.100000381469727,15.399999618530273,5135,0.0,0.0,15.130000019073487,15.307500004768372,15.188333328564962,1.7845313887403464,-1.1595622122462366,0.7845935009820384,50.81788881379942,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-19,15.5,15.5,15.100000381469727,15.449999809265137,1784,0.0,0.0,15.155000019073487,15.291249990463257,15.18125,1.9465509061060677,-0.8910322666541012,0.7245779528250735,51.2320987483889,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-20,15.600000381469727,16.0,15.199999809265137,15.399999618530273,2516,0.0,0.0,15.205000019073486,15.253749990463257,15.16875,1.282470234871264,-0.3195933552093749,0.5603625246856723,50.771610063709005,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-21,15.399999618530273,15.399999618530273,15.25,15.399999618530273,1495,0.0,0.0,15.275,15.238749980926514,15.154583326975505,0.818328108217827,0.2378805290385287,0.5553874503510108,50.771610063709005,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-22,15.5,15.550000190734863,14.850000381469727,15.550000190734863,7568,0.0,0.0,15.280000019073487,15.24249999523163,15.1449999888738,1.7670168280389038,0.2460227905762781,0.6437768664870114,52.264437077965724,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-23,15.699999809265137,15.75,15.050000190734863,15.550000190734863,4754,0.0,0.0,15.330000019073486,15.248749995231629,15.134583330154419,1.4350957037681313,0.5328307164014398,0.7543429679345215,52.26443707796572,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-26,15.149999618530273,15.899999618530273,15.149999618530273,15.899999618530273,3038,0.0,0.0,15.414999961853027,15.261249995231628,15.126249996821086,3.1462838655689795,1.0074532994966887,0.8924882137933312,55.88459802967945,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-27,16.899999618530273,18.049999237060547,16.0,16.0,7063,0.0,0.0,15.554999923706054,15.283749985694886,15.121249993642172,2.8608169622409245,1.7747603714078668,1.0746465544914496,56.890550166266635,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-28,16.0,16.0,16.0,16.0,259,0.0,0.0,15.649999904632569,15.311249995231629,15.119583320617675,2.2364223482444054,2.2124249130961675,1.2676716715637877,56.89055016626664,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-05-30,16.049999237060547,16.049999237060547,14.5,15.050000190734863,3484,0.0,0.0,15.569999885559081,15.327500009536744,15.125833320617676,-3.3397540054352164,1.5821228241491099,1.3332600237249725,45.46755683843695,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-02,14.800000190734863,15.149999618530273,14.800000190734863,15.149999618530273,1149,0.0,0.0,15.544999885559083,15.313750004768371,15.12958331902822,-2.541011707537899,1.5100800308135192,1.2172621139442006,46.68116672915825,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-03,14.800000190734863,14.850000381469727,14.0,14.399999618530273,4114,0.0,0.0,15.439999866485596,15.291249990463257,15.126249980926513,-6.735752959511161,0.9727777396557566,1.0908190050065356,39.568642836017816,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-04,14.550000190734863,14.550000190734863,14.100000381469727,14.550000190734863,562,0.0,0.0,15.354999923706055,15.279999995231629,15.129999979337056,-5.242590276593752,0.4908372283889477,0.9914079054820039,41.48880256904986,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-05,14.399999618530273,14.850000381469727,14.350000381469727,14.5,2207,0.0,0.0,15.264999961853027,15.264999985694885,15.134166646003724,-5.011463896264321,-1.5618642835093524e-07,0.8644898840578632,41.02091257620357,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-09,14.899999618530273,14.949999809265137,14.899999618530273,14.949999809265137,2713,0.0,0.0,15.204999923706055,15.268749976158142,15.142083311080933,-1.677080668993285,-0.4175197874851067,0.8365207248893894,46.83237542036631,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-10,14.899999618530273,15.25,14.600000381469727,14.949999809265137,12289,0.0,0.0,15.144999885559082,15.267499971389771,15.142499979337057,-1.2875541615545358,-0.8023585135761941,0.8254911158876358,46.83237542036631,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-11,15.0,15.0,14.949999809265137,14.949999809265137,666,0.0,0.0,15.049999904632568,15.266249966621398,15.14291664759318,-0.6644524651236026,-1.4165237858783029,0.8144621138611391,46.83237542036631,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-12,14.949999809265137,14.949999809265137,14.949999809265137,14.949999809265137,0,0.0,0.0,14.944999885559081,15.258749961853027,15.142499979337057,0.033455495111021576,-2.0561977690067876,0.7677066711216868,46.83237542036631,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-13,14.5,14.5,14.25,14.25,1257,0.0,0.0,14.769999885559082,15.203749942779542,15.139583309491476,-3.520649218606267,-2.8529149640905063,0.4238335492882268,38.82755205706774,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-16,14.300000190734863,14.699999809265137,14.0,14.449999809265137,2093,0.0,0.0,14.70999984741211,15.20874993801117,15.138333304723103,-1.7675053762336677,-3.2793628183243113,0.4651544649641015,41.88400415551787,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-17,14.5,14.5,14.0,14.0,363,0.0,0.0,14.594999885559082,15.18374993801117,15.14416663646698,-4.0767378569684,-3.8775009787154398,0.26137655834341494,37.360807968066766,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-18,14.449999809265137,14.600000381469727,14.449999809265137,14.600000381469727,466,0.0,0.0,14.614999961853027,15.161249947547912,15.153333306312561,-0.10263140898016315,-3.6029350323007665,0.052243563018923,45.77010805047426,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-19,14.600000381469727,14.600000381469727,14.350000381469727,14.350000381469727,205,0.0,0.0,14.594999980926513,15.118749976158142,15.162083307902018,-1.6786543321477512,-3.4642413959988003,-0.28580064404006755,43.169562212703596,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-23,14.050000190734863,14.399999618530273,14.050000190734863,14.399999618530273,1067,0.0,0.0,14.584999942779541,15.08624997138977,15.174583307902019,-1.2684286936926201,-3.3225621314827882,-0.5821137537677828,43.85661361748631,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-24,14.699999809265137,14.699999809265137,14.699999809265137,14.699999809265137,5,0.0,0.0,14.559999942779541,15.069999957084656,15.189583309491475,0.9615375483227465,-3.3842071384038435,-0.7872721059576078,47.924636413419904,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-25,14.350000381469727,14.699999809265137,14.350000381469727,14.699999809265137,620,0.0,0.0,14.53499994277954,15.067499947547912,15.212916644414266,1.135190004369845,-3.5340966094048696,-0.955876511160315,47.924636413419904,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-26,14.75,14.75,14.350000381469727,14.649999618530273,195,0.0,0.0,14.504999923706055,15.053749942779541,15.234999974568685,0.9996531926018124,-3.6452712524077184,-1.1896949923971067,47.262690190243895,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
2025-06-27,14.350000381469727,15.050000190734863,14.350000381469727,15.0,6022,0.0,0.0,14.50999994277954,15.038749933242798,15.259999974568684,3.376981799812434,-3.515917166056923,-1.4498692116291418,52.2360061952408,,,0.0,0.0,,732.351,106.38298,,Lipum AB (publ),Healthcare,"Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden."
